


**CUMULATIVE
SUPPLEMENT 04
April 2006**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

26th EDITION

**Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs**

Prepared By
Office of Generic Drugs
Center for Drug Evaluation and Research
Food and Drug Administration

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

26th EDITION

Cumulative Supplement 04

April 2006

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION	iii
1.1 How to use the Cumulative Supplement	iii
1.2 Applicant Name Changes.....	iv
1.3 Availability of the Edition	v
1.4 Report of Counts for the Prescription Drug Product List	vi
1.5 Cumulative Supplement Legend	vii
 DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List.....	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate <i>in vivo</i> Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
 PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

Note:

Historically, the Electronic Orange Book (EOB) and Cumulative Supplement (CS) have been updated monthly, each month updated by the end of the second full working week of the following month.

As of February 2005, we are also providing daily EOB product information for new generic drug approvals. Daily generic updates will provide the consumer with the most current listing of approved generic products. Previously, a first-time-generic approved early in the month would not be published in the CS for several weeks. Daily generic updates are especially important since the Orange Book listing may be relevant for substitution.

As a result, the monthly CS will include generic approvals and related product changes current to the day of publication (e.g., the June CS will include generic approvals up to the second week of July). Patent information is also current to the day of publication.

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

26th EDITION

**CUMULATIVE SUPPLEMENT 04
April 2006**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 25th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 25th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 26th Edition. The current edition

Section 2. How To Use The Drug Product Lists describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME
(FORMER ABBREVIATED NAME)

AVENTIS PHARMACEUTICALS INC
(AVENTIS)
AVENTIS PHARMACEUTICAL PRODUCTS INC
(AVENTIS PHARMS)

NEW APPLICANT NAME
(NEW ABBREVIATED NAME)

SANOFI AVENTIS US LLC
(SANOFI AVENTIS US)
SANOFI AVENTIS US LLC
(SANOFI AVENTIS US)

DERMIK LABORATORIES DIV AVENTIS PHARMACEUTICALS INC (DERMIK LABS)	SANOFI AVENTIS US LLC (SANOFI AVENTIS US)
DERMIK LABORATORIES INC (DERMIK LABS)	SANOFI AVENTIS US LLC (SANOFI AVENTIS US)
DERMIK LABORATORIES INC SUB RORER (DERMIK LABS)	SANOFI AVENTIS US LLC (SANOFI AVENTIS US)
CLAY PARK LABORATORIES INC (CLAY PARK)	PERRIGO NEW YORK INC (PERRIGO NEW YORK)
CLAY PARK LABS INC (CLAY PARK)	PERRIGO NEW YORK INC (PERRIGO NEW YORK)
LOREX PHARMACEUTICALS (LOREX)	SANOFI AVENTIS US LLC (SANOFI AVENTIS US)
MARTEC PHARMACEUTICALS (MARTEC)	MARTEC USA LLC (MARTEC USA LLC)
MARTEC SCIENTIFIC INC (MARTEC)	MARTEC USA LLC (MARTEC USA LLC)
PRIVATE FORMULATIONS INC (PRIVATE FMLTNS)	LEINER HEALTH PRODUCTS INC (LEINER HLTH PRODS)
PHARMACEUTICAL FORMULATIONS INC (PHARM FORM)	LEINER HEALTH PRODUCTS INC (LEINER HLTH PRODS)
SANOFI AVENTIS US INC (SANOFI AVENTIS US)	SANOFI AVENTIS US LLC (SANOFI AVENTIS US)
SANOFI-AVENTIS US INC (SANOFI AVENTIS)	SANOFI AVENTIS US LLC (SANOFI AVENTIS US)
SANOFI INC (SANOFI)	SANOFI AVENTIS US LLC (SANOFI AVENTIS US)
SANOFI SYNTHELABO INC (SANOFI SYNTHELABO)	SANOFI AVENTIS US LLC (SANOFI AVENTIS US)
SANOFI SYNTHELABO RESEARCH DIV SANOFI SYNTHELABO INC (SANOFI SYN RES)	SANOFI AVENTIS US LLC (SANOFI AVENTIS US)
STERIS LABORATORIES INC (STERIS)	WATSON LABORATORIES INC (WATSON)
UCB PHARMA INC (UCB PHARMA)	UCB INC (UCB INC)

1.3 AVAILABILITY OF THE EDITION

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements will not be available in a published paper version. Since 1997, the Electronic Orange Book (EOB) <http://www.fda.gov/cder/ob/default.htm>, has been available on the internet and has become the updated-every-month Orange Book.

The 25th edition and current monthly supplement are available in an electronic downloadable Portable Document Format (PDF) at the EOB home page by clicking on the Annual Edition. The PDF annual and cumulative supplements will duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The Electronic Orange Book Query (EOB) is at <http://www.fda.gov/cder/ob/default.htm>. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Currently, In addition to monthly updates, in the public interest, the EOB is updated on a daily basis with new generic product approval information and new patent information. Current month updates are accomplished by the third week of the following month.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/cder/rxotcdpl/pdplarchive.htm>

There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/cder/orange/obreadme.htm>. The drug product text files are zipped into eobzip.exe. The files are updated concurrently with the monthly cumulative supplements. Appendix A and Appendix B text files of the annual Orange Book Edition are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.4 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2004) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2005</u>	<u>MAR 2006</u>	<u>SEP 2006</u>	<u>DEC 2006</u>
DRUG PRODUCTS LISTED	11368	11487		
SINGLE SOURCE	2428 (21.4%)	2461 (21.4%)		
MULTISOURCE	8851 (77.9%)	8937 (77.8%)		
THERAPEUTICALLY EQUIVALENT	8642 (76.04%)	8730 (76.0%)		
NOT THERAPEUTICALLY EQUIVALENT	209 (1.8%)	207 (1.8%)		
EXCEPTIONS ¹	89 (0.8%)	89 (0.8%)		
NEW MOLECULAR ENTITIES				
APPROVED	11	6		
NUMBER OF APPLICANTS	628	629		

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.5 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.

DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.
WDAG	Withdrawn. The applicant holder has notified the FDA in writing that the product is no longer being marketed resulting in the product approval being withdrawn by mutual agreement. The product will be listed in the Discontinued Section.
WDRP	Withdrawn. The application approval has been withdrawn for failure to provide Annual Reports. The product will be moved to the Discontinued Section in the next edition

PRESCRIPTION DRUG PRODUCT LIST - 26TH EDITION

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLIMENT 4 - April 2006

1-1

ACETAMINOPHEN; BUTALBITAL

TABLET; ORAL
BUTAPAP

AB + MIKART	650MG;50MG	N89988 001 Oct 26, 1992 Jan CRLD
SEDAPAP		
@ MAYRAND	650MG;50MG	N88944 001 Oct 17, 1985 Jan DISC

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION; ORAL
ACETAMINOPHEN AND CODEINE PHOSPHATE
@ CLONMEL 120MG/5ML;12MG/5ML N40098 001 Sep 20, 1996 Jan DISC

TABLET; ORAL
ACETAMINOPHEN AND CODEINE PHOSPHATE

>D> AA TEVA	300MG;60MG	N88629 001 Mar 06, 1985 Apr CRLD
>A> AA +	300MG;60MG	N88629 001 Mar 06, 1985 Apr CRLD

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL
HYDROCODONE BITARTRATE AND ACETAMINOPHEN

@ ENDO PHARMS	500MG;7.5MG	N40280 001 Sep 30, 1998 Feb DISC
@	650MG;7.5MG	N40280 002 Sep 30, 1998 Feb DISC
@	650MG;10MG	N40280 003 Sep 30, 1998 Feb DISC
@	750MG;7.5MG	N40281 002 Sep 30, 1998 Feb DISC
MIKART	300MG;5MG	N40658 001 Jan 19, 2006 Jan NEWA
+	300MG;7.5MG	N40556 002 Mar 24, 2006 Mar NEWA
AA VINTAGE PHARMS	325MG;5MG	N40655 001 Jan 19, 2006 Jan NEWA
AA	325MG;7.5MG	N40656 001 Jan 19, 2006 Jan NEWA
HY-PHEN		
@ ASCHER	500MG;5MG	N87677 001 May 03, 1982 Mar DISC

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL
OXYCODONE AND ACETAMINOPHEN

>A> + MIKART	400MG;5MG	N40687 001 Apr 27, 2006 Apr NEWA
>A> +	400MG;7.5MG	N40698 001 Apr 27, 2006 Apr NEWA
>A> +	400MG;10MG	N40692 001 Apr 27, 2006 Apr NEWA
>A>	500MG;10MG	N40676 001 Apr 19, 2006 Apr NEWA

ACETAZOLAMIDE

TABLET; ORAL
ACETAZOLAMIDE

AB + TARO	250MG	N40195 002 May 28, 1997 Mar CRLD
DIAMOX		
@ DURAMED PHARMS BARR	125MG	N08943 001 Mar DISC
@	250MG	N08943 002 Mar DISC

ACETIC ACID, GLACIAL; HYDROCORTISONE

SOLUTION/DROPS; OTIC
HYDROCORTISONE AND ACETIC ACID

AT VINTAGE	2%;1%	N40609 001 Feb 06, 2006 Jan NEWA
------------	-------	----------------------------------

ALBUTEROL

AEROSOL, METERED; INHALATION

ALBUTEROL

@ GENPHARM

0.09MG/INH

N73045 001 Aug 19, 1997 Feb DISC

@ PLIVA

0.09MG/INH

N74072 001 Aug 01, 1996 Feb DISC

ALBUTEROL SULFATE

SOLUTION; INHALATION

ALBUTEROL SULFATE

AN RXELITE EQ 0.083% BASE N77569 001 Apr 04, 2006 Mar NEWA

ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN K

INJECTABLE; INJECTION

INFUVITE ADULT

+ SANDOZ 2 IU/ML;40MG/ML;12UGM/ML;40 IU/ML;1UGM/ML;3MG/ML;120UGM/ML;8M G/ML;1.2MG/ML;0.72MG/ML;1.2MG/ML; 660 IU/ML;0.03MG/ML N21163 001 May 18, 2000 Jan CAHN

INJECTABLE; IV (INFUSION)

INFUVITE ADULT

+ SANDOZ 2 IU/ML;40MG/ML;12UGM/ML;40 IU/ML;1UGM/ML;3MG/ML;120UGM/ML;8M G/ML;1.2MG/ML;0.72MG/ML;1.2MG/ML; 660 IU/ML;30UGM/ML N21559 001 Jun 16, 2003 Jan CAHN

ALPRAZOLAM

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

AB MYLAN 0.5MG N77391 002 Jan 26, 2006 Jan NEWA
AB 1MG N77391 003 Jan 26, 2006 Jan NEWA
AB 2MG N77391 004 Jan 26, 2006 Jan NEWA
AB 3MG N77391 001 Jan 26, 2006 Jan NEWA

XANAX XR

AB PHARMACIA AND UPJOHN 0.5MG N21434 001 Jan 17, 2003 Jan CFTG
AB 1MG N21434 002 Jan 17, 2003 Jan CFTG
AB 2MG N21434 003 Jan 17, 2003 Jan CFTG
AB + 3MG N21434 004 Jan 17, 2003 Jan CFTGAMANTADINE HYDROCHLORIDE

CAPSULE; ORAL

AMANTADINE HYDROCHLORIDE

AB AMIDE PHARM 100MG N77659 001 Feb 23, 2006 Feb NEWA

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE; ORAL

LOTREL

>A> NOVARTIS EQ 5MG BASE;40MG N20364 007 Apr 11, 2006 Apr NEWA
>D> + EQ 10MG BASE;20MG N20364 005 Jun 20, 2002 Apr CRLD
>A> EQ 10MG BASE;20MG N20364 005 Jun 20, 2002 Apr CRLD
>A> + EQ 10MG BASE;40MG N20364 006 Apr 11, 2006 Apr NEWAAMMONIUM LACTATE

CREAM; TOPICAL

AMMONIUM LACTATE

AB PADDOCK EQ 12% BASE N76829 001 Feb 07, 2006 Jan NEWA

AMOXICILLIN

CAPSULE; ORAL				
AMOXICILLIN				
AB AM ANTIBIOTICS	250MG	N62058 001	Jan	CAHN
AB	500MG	N62058 002	Jan	CAHN
FOR SUSPENSION; ORAL				
AMOXICILLIN				
AB AM ANTIBIOTICS	125MG/5ML	N62059 001	Jan	CAHN
AB	250MG/5ML	N62059 002	Jan	CAHN
TABLET; ORAL				
AMOXICILLIN				
AB HIKMA	875MG	N65255 001 Mar 29, 2006	Mar	NEWA

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL				
AMPICILLIN TRIHYDRATE				
@ AM ANTIBIOTICS	EQ 250MG BASE	N61602 001	Jan	CAHN
@	EQ 500MG BASE	N61602 002	Jan	CAHN
FOR SUSPENSION; ORAL				
AMPICILLIN TRIHYDRATE				
@ AM ANTIBIOTICS	EQ 125MG BASE/5ML	N61601 001	Jan	CAHN
@	EQ 250MG BASE/5ML	N61601 002	Jan	CAHN

ANIDULAFUNGIN

INJECTABLE; IV (INFUSION)				
ERAXIS				
+ VICURON	50MG/VIAL	N21632 001 Feb 17, 2006	Feb	NEWA

ANISINDIONE

TABLET; ORAL				
MIRADON				
@ SCHERING	50MG	N10909 003	Jan	DISC

>D> ARTICAINE HYDROCHLORIDE; EPINEPHRINE

>D>	INJECTABLE; INJECTION				
>D>	SEPTOCAIN				
>D>	DEPROCO	4%;EQ 0.005MG BASE/ML	N22010 001 Mar 30, 2006	Apr	CAIN
		4%;EQ 0.005MG BASE/ML	N22010 001 Mar 30, 2006	Mar	NEWA
>D>	+	4%; EQ 0.017MG BASE/1.7ML (4%; EQ 0.01MG BASE/ML)	N20971 001 Apr 03, 2000	Apr	CAIN
	+	4%; EQ 0.017MG BASE/1.7ML (4%; EQ 0.01MG BASE/ML)	N20971 001 Apr 03, 2000	Mar	CPOT

>A> ARTICAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

>A>	INJECTABLE; INJECTION				
>A>	SEPTOCAIN				
>A>	+ DEPROCO	4%;EQ 0.0085MG BASE/1.7ML(4%; EQ 0.005MG BASE/ML)	N22010 001 Mar 30, 2006	Apr	CAIN
>A>	+	4%; EQ 0.017MG BASE/1.7ML (4%; EQ 0.01MG BASE/ML)	N20971 001 Apr 03, 2000	Apr	CAIN

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID;
NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

INJECTABLE; IV (INFUSION)

INFUVITE PEDIATRIC

+ Sandoz	80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.1 4MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG /VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL	N21265 001 Feb 21, 2001 Jan CAHN
+ Sandoz	80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.1 4MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG /VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL	N21646 001 Jan 29, 2004 Jan CAHN

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE

@ ENDO PHARMS 325MG;50MG;40MG;30MG

N75351 001 Mar 05, 1999 Feb DISC

FIORINAL W/CODEINE

>A> AB + WATSON PHARMS 325MG;50MG;40MG;30MG

N19429 003 Oct 26, 1990 Apr CTNA

FIORINAL W/CODEINE NO 3

>D> AB + WATSON PHARMS 325MG;50MG;40MG;30MG

N19429 003 Oct 26, 1990 Apr CTNA

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET; ORAL

PERCODAN-DEMI

@ ENDO PHARMS 325MG;2.25MG;0.19MG

N07337 005 Feb DISC

BACAMPICILLIN HYDROCHLORIDE

FOR SUSPENSION; ORAL

SPECTROBID

@ PFIZER 125MG/5ML

N50556 001 Mar 23, 1982 Feb DISC

TABLET; ORAL

SPECTROBID

@ PFIZER 400MG

N50520 001 Feb DISC

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE

AB APOTEX INC	5MG	N77128 001 Mar 08, 2006 Feb NEWA
AB	10MG	N77128 002 Mar 08, 2006 Feb NEWA
AB	20MG	N77128 003 Mar 08, 2006 Feb NEWA
AB	40MG	N77128 004 Mar 08, 2006 Feb NEWA
AB BIOKEY	5MG	N76820 001 Feb 03, 2006 Jan NEWA
AB	10MG	N76820 002 Feb 03, 2006 Jan NEWA
AB	20MG	N76820 003 Feb 03, 2006 Jan NEWA
AB	40MG	N76820 004 Feb 03, 2006 Jan NEWA

BENZPHETAMINE HYDROCHLORIDE

TABLET; ORAL

BENZPHETAMINE HYDROCHLORIDE

>A> AA PADDOCK	50MG	N40578 001 Apr 17, 2006 Apr NEWA
DIDREX		
>D> + PHARMACIA AND UPJOHN	50MG	N12427 002 Apr CFTG
>A> AA +	50MG	N12427 002 Apr CFTG

BENZQUINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION
 EMETE-CON
 @ PFIZER EQ 50MG BASE/VIAL N16820 001 Mar DISC

BETAINA, ANHYDROUS

FOR SOLUTION; ORAL
 CYSTADANE
 + JAZZ 1GM/SCOOPFUL N20576 001 Oct 25, 1996 Feb CAHN

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE

OINTMENT; TOPICAL
 TACLONEX
 + LEO PHARM PRODS 0.064%;0.005% N21852 001 Jan 09, 2006 Jan NEWA

BRIMONIDINE TARTRATE

SOLUTION/DROPS; OPHTHALMIC
 BRIMONIDINE TARTRATE
 AT AKORN 0.2% N76439 001 Mar 14, 2006 Feb NEWA

BRINZOLAMIDE

SUSPENSION/DROPS; OPHTHALMIC
 AZOPT
 + ALCON 1% N20816 001 Apr 01, 1998 Feb CAHN

BUDESONIDE

SPRAY, METERED; NASAL
 RHINOCORT
 + ASTRazeneca 0.032MG/INH N20746 001 Oct 01, 1999 Mar CRLD
 @ 0.064MG/INH N20746 002 Oct 01, 1999 Mar DISC

BUMETANIDE

INJECTABLE; INJECTION
 BUMETANIDE
 AP + BEDFORD 0.25MG/ML N74441 001 Jan 27, 1995 Feb CRLD
 BUMEX
 @ ROCHE 0.25MG/ML N18226 001 Feb 28, 1983 Feb DISC

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION
 BUPIVACAINE HYDROCHLORIDE
 >A> + HOSPIRA 0.5% N22046 002 Jul 13, 1983 Apr NEWA

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION
 BUPIVACAINE HYDROCHLORIDE W/EPINEPHRINE
 >A> + HOSPIRA 0.5%;EQ 0.009MG BASE/ML N22046 001 Jul 13, 1983 Apr NEWA

BUPROPION HYDROCHLORIDE

TABLET; ORAL
 BUPROPION HYDROCHLORIDE
 AB APOTEX INC 75MG N76143 001 Jan 17, 2006 Jan NEWA
 AB 100MG N76143 002 Jan 17, 2006 Jan NEWA

BUSULFAN

INJECTABLE; INJECTION
 BUSULFEX
 + PDL BIOPHARMA INC 6MG/ML N20954 001 Feb 04, 1999 Jan CAHN

CAFFEINE; ERGOTAMINE TARTRATE

SUPPOSITORY; RECTAL
 CAFERGOT
 @ NOVARTIS 100MG;2MG N09000 002 Feb DISC
 MIGERGOT
 + G AND W LABS 100MG;2MG N86557 001 Oct 04, 1983 Feb CRLD

CALCIPOTRIENE

CREAM; TOPICAL
 DOVONEX
 + LEO PHARM 0.005% N20554 001 Jul 22, 1996 Feb CAHN
 OINTMENT; TOPICAL
 DOVONEX
 + LEO PHARM 0.005% N20273 001 Dec 29, 1993 Feb CAHN
 SOLUTION; TOPICAL
 DOVONEX
 + LEO PHARM 0.005% N20611 001 Mar 03, 1997 Feb CAHN

CALCITONIN, SALMON

INJECTABLE; INJECTION
 MIACALCIN
 + NOVARTIS 200 IU/ML N17808 002 Mar 29, 1991 Jan CTEC

CALCITRIOL

CAPSULE; ORAL
 CALCITRIOL
 AB ROXANE 0.25UGM N76917 001 Mar 27, 2006 Mar NEWA
 INJECTABLE; INJECTION
 CALCITRIOL
 AP GENIX THERAP 0.001MG/ML N77102 001 Feb 08, 2006 Jan NEWA

CAPTOPRIL

TABLET; ORAL
 CAPTOPRIL
 @ CLONMEL HLTHCARE 12.5MG N74423 001 Feb 13, 1996 Jan DISC
 @ 25MG N74423 002 Feb 13, 1996 Jan DISC
 @ 50MG N74423 003 Feb 13, 1996 Jan DISC
 @ 100MG N74423 004 Feb 13, 1996 Jan DISC
 @ ENDO LABS 12.5MG N74418 001 Feb 13, 1996 Feb DISC
 @ 25MG N74418 002 Feb 13, 1996 Feb DISC
 @ 50MG N74418 003 Feb 13, 1996 Feb DISC
 @ 100MG N74418 004 Feb 13, 1996 Feb DISC

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL
 CAPTOPRIL AND HYDROCHLOROTHIAZIDE
 @ ENDO LABS 25MG;15MG N74788 001 Dec 29, 1997 Feb DISC
 @ 25MG;25MG N74788 002 Dec 29, 1997 Feb DISC
 @ 50MG;15MG N74788 004 Dec 29, 1997 Feb DISC

TABLET; ORAL

CAPTOPRIL AND HYDROCHLOROTHIAZIDE
 @ ENDO LABS 50MG;25MG

N74788 003 Dec 29, 1997 Feb DISC

CARBOPLATIN

INJECTABLE; INJECTION

CARBOPLATIN

AP	WATSON LABS	50MG/VIAL	N77383 001 Jan 27, 2006 Jan NEWA
AP		150MG/VIAL	N77383 002 Jan 27, 2006 Jan NEWA
AP		450MG/VIAL	N77383 003 Jan 27, 2006 Jan NEWA

INJECTABLE; IV (INFUSION)

CARBOPLATIN

AP	@ AM PHARM	EQ 50MG/5ML (10MG/ML)	N77247 001 Oct 21, 2004 Feb DISC
AP		EQ 50MG/5ML (10MG/ML)	N77266 001 Feb 15, 2006 Jan NEWA
	@	EQ 150MG/15ML (10MG/ML)	N77247 002 Oct 21, 2004 Feb DISC
AP		EQ 150MG/15ML (10MG/ML)	N77266 002 Feb 15, 2006 Jan NEWA
AP		EQ 450MG/45ML (10MG/ML)	N77266 003 Feb 15, 2006 Jan NEWA
AP		EQ 600MG/60ML (10MG/ML)	N77266 004 Feb 15, 2006 Jan NEWA
AP	BEDFORD LABS	EQ 600MG/60ML (10MG/ML)	N77244 004 Jan 20, 2006 Jan NEWA

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE; ORAL

CEFADROXIL

AB	+	IVAX PHARMS	EQ 500MG BASE	N62766 001 Mar 03, 1987 Mar CRLD
AB		TEVA PHARMS	EQ 500MG BASE	N65282 001 Jan 20, 2006 Jan NEWA
AB		WESTWARD	EQ 500MG BASE	N65311 001 Feb 07, 2006 Jan NEWA

DURICEF

@ WARNER CHILCOTT

EQ 500MG BASE

N50512 001 Jan DISC

FOR SUSPENSION; ORAL

CEFADROXIL

	RANBAXY	EQ 125MG BASE/5ML	N65115 001 Mar 26, 2003 Feb CTEC
AB	TEVA PHARMS	EQ 250MG BASE/5ML	N65278 001 Jan 20, 2006 Jan NEWA
AB		EQ 500MG BASE/5ML	N65278 002 Jan 20, 2006 Jan NEWA

DURICEF

@ WARNER CHILCOTT

EQ 125MG BASE/5ML

N50527 002 Feb DISC

TABLET; ORAL

CEFADROXIL

AB	HIKMA	EQ 1GM BASE	N65260 001 Mar 30, 2006 Mar NEWA
AB	+	IVAX PHARMS	N62774 001 Apr 08, 1987 Feb CRLD
	DURICEF		
	@ WARNER CHILCOTT	EQ 1GM BASE	N50528 001 Jan DISC

CEFOXITIN SODIUM

INJECTABLE; INJECTION

CEFOXITIN

AP	ORCHID HLTHCARE	EQ 1GM BASE/VIAL	N65313 001 Jan 23, 2006 Jan NEWA
AP		EQ 2GM BASE/VIAL	N65313 002 Jan 23, 2006 Jan NEWA
AP		EQ 10GM BASE/VIAL	N65312 001 Feb 13, 2006 Jan NEWA

CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER

AP	B BRAUN	EQ 1GM BASE/VIAL	N65214 001 Mar 10, 2006 Feb NEWA
AP		EQ 2GM BASE/VIAL	N65214 002 Mar 10, 2006 Feb NEWA

CEFTRIAXONE

INJECTABLE; INJECTION
CEFTRIAXONE

>A> AP TEVA EQ 10GM BASE/VIAL N65274 001 May 01, 2006 Apr NEWA

CEFTRIAXONE SODIUM

INJECTABLE; IM-IV
CEFTRIAXONE

AP	AM PHARM PARTNERS	EQ 250MG BASE/VIAL	N65245 001 Feb 15, 2006 Jan NEWA
AP		EQ 500MG BASE/VIAL	N65245 002 Feb 15, 2006 Jan NEWA
AP		EQ 1GM BASE/VIAL	N65245 003 Feb 15, 2006 Jan NEWA
AP		EQ 2GM BASE/VIAL	N65245 004 Feb 15, 2006 Jan NEWA

INJECTABLE; INJECTION
CEFTRIAXONE

AP AM PHARM EQ 10GM BASE/VIAL N65252 001 Feb 15, 2006 Jan NEWA

CEFUROXIME AXETIL

TABLET; ORAL
CEFUROXIME AXETIL

AB	AUROBINDO PHARMA LTD	EQ 125MG BASE	N65308 001 Mar 29, 2006 Mar NEWA
AB		EQ 250MG BASE	N65308 002 Mar 29, 2006 Mar NEWA
AB		EQ 500MG BASE	N65308 003 Mar 29, 2006 Mar NEWA

CEPHALEXIN

CAPSULE; ORAL
CEPHALEXIN

AB	HIKMA	EQ 250MG BASE	N65215 001 Jan 24, 2006 Jan NEWA
AB		EQ 500MG BASE	N65215 002 Jan 24, 2006 Jan NEWA

CEPHRADINE

CAPSULE; ORAL
ANSPOR
@ GLAXOSMITHKLINE

250MG	N61859 001 Mar DISC
500MG	N61859 002 Mar DISC

CICLOPIROX

CREAM; TOPICAL
CICLOPIROX
AB PERRIGO 0.77%
AB PERRIGO NEW YORK 0.77%

N77364 001 Mar 03, 2006 Mar CAHN
N77364 001 Mar 03, 2006 Feb NEWA

CILOSTAZOL

TABLET; ORAL
CILOSTAZOL
AB MUTUAL PHARM 50MG
AB 100MG
>A> AB MYLAN 50MG
>A> AB 100MG

N77208 002 Mar 29, 2006 Mar NEWA
N77208 001 Mar 29, 2006 Mar NEWA
N77323 002 Apr 20, 2006 Apr NEWA
N77323 001 Apr 20, 2006 Apr NEWA

CIMETIDINE

TABLET; ORAL
CIMETIDINE
@ ENDO PHARMS 200MG
@ 300MG

N74281 001 May 17, 1994 Feb DISC
N74281 002 May 17, 1994 Feb DISC

TABLET; ORAL

CIMETIDINE

@ ENDO PHARMS	400MG	N74281 003 May 17, 1994 Feb DISC
@	800MG	N74329 001 May 17, 1994 Feb DISC

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CIMETIDINE HYDROCHLORIDE

@ ENDO PHARMS	EQ 300MG BASE/2ML	N74005 001 Aug 31, 1994 Feb DISC
---------------	-------------------	----------------------------------

SOLUTION; ORAL

CIMETIDINE HYDROCHLORIDE

@ ENDO PHARMS	EQ 300MG BASE/5ML	N74251 001 Dec 22, 1994 Feb DISC
---------------	-------------------	----------------------------------

CITALOPRAM HYDROBROMIDE

TABLET; ORAL

CITALOPRAM HYDROBROMIDE

AB TARO	EQ 10MG BASE	N77278 001 Mar 22, 2006 Mar NEWA
AB	EQ 20MG BASE	N77278 002 Mar 22, 2006 Mar NEWA
AB	EQ 40MG BASE	N77278 003 Mar 22, 2006 Mar NEWA
AB TEVA PHARMS	EQ 10MG BASE	N77213 001 Mar 31, 2006 Mar NEWA
AB	EQ 20MG BASE	N77213 002 Mar 31, 2006 Mar NEWA
AB	EQ 40MG BASE	N77213 003 Mar 31, 2006 Mar NEWA

CLARITHROMYCIN

TABLET, EXTENDED RELEASE; ORAL

CLARITHROMYCIN

>D> RANBAXY	1GM	N65210 001 Jan 26, 2005 Apr CRLD
>A> +	1GM	N65210 001 Jan 26, 2005 Apr CRLD

CLINDAMYCIN PHOSPHATE

SOLUTION; TOPICAL

CLINDAMYCIN PHOSPHATE

AT ALTANA	EQ 1% BASE	N65254 001 Feb 14, 2006 Jan NEWA
-----------	------------	----------------------------------

CLOBETASOL PROPIONATE

SPRAY; TOPICAL

CLOBEX

+ GALDERMA LABS LP	0.05%	N21835 001 Oct 27, 2005 Feb CAHN
--------------------	-------	----------------------------------

CLOPIDOGREL BISULFATE

TABLET; ORAL

CLOPIDOGREL BISULFATE

AB APOTEX	EQ 75MG BASE	N76274 001 Jan 20, 2006 Jan NEWA
PLAVIX		
AB + SANOFI SYNTHELABO	EQ 75MG BASE	N20839 001 Nov 17, 1997 Jan CFTG

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETH VC W/ CODEINE

+ ALPHARMA US PHARMS	10MG/5ML;5MG/5ML;6.25MG/5ML	N88764 001 Oct 31, 1984 Jan CTEC
----------------------	-----------------------------	----------------------------------

PROMETHAZINE VC W/ CODEINE

@ MORTON GROVE	10MG/5ML;5MG/5ML;6.25MG/5ML	N88896 001 Jan 04, 1985 Jan DISC
----------------	-----------------------------	----------------------------------

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE WITH CODEINE SYRUP

AA VINTAGE 10MG/5ML; 6.25MG/5ML N40650 001 Jan 31, 2006 Jan NEWA

COLESTIPOL HYDROCHLORIDE

GRANULE; ORAL

COlestid

>D>	+ PHARMACIA AND UPJOHN	5GM/PACKET	N17563 004 Sep 22, 1995 Apr CFTG
>D>		5GM/SCOOPFUL	N17563 003 Sep 22, 1995 Apr CFTG
>A> AB		5GM/SCOOPFUL	N17563 003 Sep 22, 1995 Apr CFTG
>A> AB	+	5GM/PACKET	N17563 004 Sep 22, 1995 Apr CFTG
>A>	COLESTIPOL HYDROCHLORIDE		
>A> AB	IMPAKX LABS	5GM/SCOOPFUL	N77277 001 May 02, 2006 Apr NEWA
>A> AB		5GM/PACKET	N77277 002 May 02, 2006 Apr NEWA
	FLAVORED COlestid		
>D>	+ PHARMACIA AND UPJOHN	5GM/PACKET	N17563 001 Apr CRLD
>A>		5GM/PACKET	N17563 001 Apr CRLD

CROMOLYN SODIUM

SOLUTION, CONCENTRATE; ORAL

GASTROCROM

+ AZUR PHARMA 100MG/5ML

N20479 001 Feb 29, 1996 Feb CAHN

CYANOCOBALAMIN

GEL, METERED; NASAL

NASCOBAL

@ QOL MEDCL 0.5MG/INH

N19722 001 Nov 05, 1996 Mar DISC

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

>A> AB	JUBILANT PHARMS	5MG	N77563 001 Apr 19, 2006 Apr NEWA
>A> AB		10MG	N77563 002 Apr 19, 2006 Apr NEWA
	CYCLOBENZAPRINE HYDROCHLORIDE		
AB	AMIDE PHARM	5MG	N77291 001 Feb 03, 2006 Jan NEWA
AB	MUTUAL PHARM	5MG	N73541 002 Apr 06, 2006 Mar NEWA
AB	MYLAN	5MG	N73144 002 Feb 03, 2006 Jan NEWA
AB	SANDOZ	5MG	N72854 002 Feb 03, 2006 Jan NEWA
AB	WATSON LABS	5MG	N71611 002 Feb 03, 2006 Jan NEWA
		7.5MG	N71611 003 Feb 03, 2006 Jan NEWA
	FLEXERIL		
AB	MCNEIL CONS SPECLT	5MG	N17821 001 Jan CFTG

DEFEROXAMINE MESYLATE

INJECTABLE; INJECTION

DEFEROXAMINE MESYLATE

AP SICOR PHARMS 500MG/VIAL N76806 001 Mar 31, 2006 Mar NEWA
AP 2GM/VIAL N76806 002 Mar 31, 2006 Mar NEWADEMECLOCYCLINE HYDROCHLORIDE

TABLET; ORAL

DECLOMYCIN

@ GLADES PHARMS LLC 75MG

N50261 001 Mar CAHN

TABLET; ORALDECLOMYCIN

AB	GLADES PHARMS LLC	150MG	N50261 002	Mar	CAHN
AB	+	300MG	N50261 003	Mar	CAHN
	@ PROTEIN DESIGN LABS	75MG	N50261 001	Feb	CAHN
AB		150MG	N50261 002	Feb	CAHN
AB	+	300MG	N50261 003	Feb	CAHN

DESLORATADINE; PSEUDOEPHEDRINE SULFATETABLET, EXTENDED RELEASE; ORALCLARINEX-D 12 HOUR

+ SCHERING	2.5MG;120MG	N21313 001 Feb 01, 2006 Feb NEWA
------------	-------------	----------------------------------

DESMOPRESSIN ACETATEINJECTABLE; INJECTIONDESMOPRESSIN ACETATE

@ BEDFORD	0.004MG/ML	N74575 001 Feb 18, 2000 Jan DISC
DESMOPRESSIN ACETATE PRESERVATIVE FREE		
@ BEDFORD	0.004MG/ML	N74574 001 Feb 18, 2000 Jan DISC

TABLET; ORALDESMOPRESSIN ACETATE

AB	APOTEX	0.1MG	N77414 001 Mar 07, 2006 Feb NEWA
AB		0.2MG	N77414 002 Mar 07, 2006 Feb NEWA
AB	TEVA PHARMS	0.1MG	N77122 001 Jan 25, 2006 Jan NEWA
AB		0.2MG	N77122 002 Jan 25, 2006 Jan NEWA

DESOGESTREL; ETHINYLPROMETHAZINE HYDROCHLORIDETABLET; ORAL-28MIRCETTE

AB	+	DURAMED	0.15MG,N/A;0.02MG,0.01MG	N20713 001 Apr 22, 1998 Feb CAHN
AB	+		0.15MG,N/A;0.02MG,0.01MG	N20713 001 Apr 22, 1998 Feb CAHN

DEXAMETHASONE SODIUM PHOSPHATEINJECTABLE; INJECTIONDEXAMETHASONE

AP	BAXTER HLTHCARE	EQ 10MG PHOSPHATE/ML	N87702 001 Sep 07, 1982 Mar CAHN
----	-----------------	----------------------	----------------------------------

DEXTRAMPHETAMINE SULFATETABLET; ORALDEXTRAMPHETAMINE SULFATE

@ ENDO PHARMS	5MG	N40299 001 May 13, 1999 Feb DISC
---------------	-----	----------------------------------

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDESYRUP; ORALPROMETHAZINE DM

AA	VINTAGE	15MG/5ML;6.25MG/5ML	N40649 001 Feb 14, 2006 Jan NEWA
----	---------	---------------------	----------------------------------

DIAZEPAMTABLET; ORALDIAZEPAM

AB	VINTAGE PHARMS	2MG	N77749 001 Mar 31, 2006 Mar NEWA
AB		5MG	N77749 002 Mar 31, 2006 Mar NEWA
AB		10MG	N77749 003 Mar 31, 2006 Mar NEWA

DIFLORASONE DIACETATE

CREAM; TOPICAL

DIFLORASONE DIACETATE

BX	+	ALTANA	0.05%	N76263 001 Dec 20, 2002 Jan CRLD
		FLORONE		
	@	PHARMACIA AND UPJOHN	0.05%	N17741 001 Jan DISC
		FLORONE E		
	@	PHARMACIA AND UPJOHN	0.05%	N19259 001 Aug 28, 1985 Jan DISC
		OINTMENT; TOPICAL		
		DIFLORASONE DIACETATE		
AB	+	TARO	0.05%	N75331 001 May 14, 1999 Jan CRLD
		FLORONE		
	@	PHARMACIA AND UPJOHN	0.05%	N17994 001 Jan DISC
		PSORCON		
	@	PHARMACIA AND UPJOHN	0.05%	N19260 001 Aug 28, 1985 Jan DISC

DIGOXIN

INJECTABLE; INJECTION

DIGOXIN

AP		SANDOZ	0.25MG/ML	N40481 001 Aug 21, 2003 Jan CAHN
----	--	--------	-----------	----------------------------------

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

DILTZAC

AB4		APOTEX INC	120MG	N76395 001 Feb 01, 2006 Jan NEWA
AB4			180MG	N76395 002 Feb 01, 2006 Jan NEWA
AB4			240MG	N76395 003 Feb 01, 2006 Jan NEWA
AB4			300MG	N76395 004 Feb 01, 2006 Jan NEWA
AB4			360MG	N76395 005 Feb 01, 2006 Jan NEWA

DIPYRIDAMOLE

TABLET; ORAL

DIPYRIDAMOLE

>A>	AB	AMIDE PHARM	25MG	N40542 001 Apr 21, 2006 Apr NEWA
>A>	AB		50MG	N40542 002 Apr 21, 2006 Apr NEWA
>A>	AB		75MG	N40542 003 Apr 21, 2006 Apr NEWA

DISOPYRAMIDE PHOSPHATE

CAPSULE; ORAL

DISOPYRAMIDE PHOSPHATE

@	IVAX PHARMS	EQ 100MG BASE	N70186 001 Nov 18, 1985 Jan DISC
@		EQ 150MG BASE	N70187 001 Nov 18, 1985 Jan DISC
@	SANDOZ	EQ 100MG BASE	N70470 001 Dec 10, 1985 Jan DISC
@		EQ 150MG BASE	N70471 001 Dec 10, 1985 Jan DISC

DOLASETRON MESYLATE

INJECTABLE; INJECTION

ANZEMET

+	SANOFI AVENTIS US	EQ 12.5MG BASE/0.625ML (EQ 20MG BASE/ML)	N20624 002 Sep 11, 1997 Mar CAIN
+		EQ 100MG BASE/5ML (EQ 20MG BASE/ML)	N20624 001 Sep 11, 1997 Mar CAIN
+		EQ 500MG BASE/25ML (EQ 20MG BASE/ML)	N20624 003 Dec 11, 2001 Mar CAIN

TABLET; ORAL

ANZEMET

SANOFI AVENTIS US	EQ 50MG BASE	N20623 001 Sep 11, 1997 Mar CAIN
+	EQ 100MG BASE	N20623 002 Sep 11, 1997 Mar CAIN

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOPAMINE HYDROCHLORIDE

>D> AP + HOSPIRA	40MG/ML	N74403 001 May 23, 1996 Apr DISC
>A> @	40MG/ML	N74403 001 May 23, 1996 Apr DISC
>D> AP + INTL MEDICATION	40MG/ML	N18014 001 Apr DISC
>A> @	40MG/ML	N18014 001 Apr DISC
>D> AP + SICOR PHARMS	40MG/ML	N72999 001 Oct 23, 1991 Apr DISC
>A> @	40MG/ML	N72999 001 Oct 23, 1991 Apr DISC
>D> AP +	80MG/ML	N73000 001 Oct 23, 1991 Apr DISC
>A> @	80MG/ML	N73000 001 Oct 23, 1991 Apr DISC

DOXYCYCLINE

CAPSULE; ORAL

DOXYCYCLINE

@ PAR PHARM	EQ 75MG BASE	N65055 004 Apr 18, 2005 Mar DISC
@	EQ 150MG BASE	N65055 003 Jul 15, 2005 Mar DISC
RANBAXY	EQ 75MG BASE	N65053 003 Sep 10, 2003 Mar CTEC

TABLET; ORAL

DOXYCYCLINE

PAR PHARM	EQ 75MG BASE	N65070 003 Dec 30, 2002 Mar CMFD
-----------	--------------	----------------------------------

DOXYCYCLINE HYCLATE

CAPSULE, DELAYED RELEASE; ORAL

DORYX

>D> AB FH FAULDING CO LTD	EQ 75MG BASE	N50582 002 Aug 13, 2001 Apr DISC
>A> @	EQ 75MG BASE	N50582 002 Aug 13, 2001 Apr DISC
>D> AB +	EQ 100MG BASE	N50582 001 Jul 22, 1985 Apr DISC
>A> @	EQ 100MG BASE	N50582 001 Jul 22, 1985 Apr DISC
>D> AB WARNER CHILCOTT	EQ 100MG BASE	N62653 001 Oct 30, 1985 Apr DISC
>A> @	EQ 100MG BASE	N62653 001 Oct 30, 1985 Apr DISC

DOXYCYCLINE HYCLATE

>D> AB SANDOZ	EQ 75MG BASE	N65281 001 Dec 21, 2005 Apr CTEC
>A>	EQ 75MG BASE	N65281 001 Dec 21, 2005 Apr CTEC
>D> AB	EQ 100MG BASE	N65281 002 Dec 21, 2005 Apr CRLD
>A> +	EQ 100MG BASE	N65281 002 Dec 21, 2005 Apr CRLD

TABLET; ORAL

DOXYCYCLINE HYCLATE

AB PAR PHARM	EQ 20MG BASE	N65287 001 Feb 28, 2006 Feb NEWA
--------------	--------------	----------------------------------

DROSPIRENONE; ETHINYLL ESTRADIOL

TABLET; ORAL

YAZ

+ BERLEX LABS	3MG; 0.02MG	N21676 001 Mar 16, 2006 Mar NEWA
---------------	-------------	----------------------------------

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

XYLOCAINE W/ EPINEPHRINE

+ DENTSPLY PHARM	0.02MG/ML; 2%	N21381 002 Mar CRLD
------------------	---------------	---------------------

ERYTHROMYCIN

SOLUTION; TOPICAL

A/T/S

AT TARO PHARMS NORTH 2% N62405 001 Nov 18, 1982 Feb CAHN

ESTAZOLAM

TABLET; ORAL

ESTAZOLAM

>D>	AB	IVAX PHARMS	1MG	N74826 001 Jul 03, 1997 Apr CAHN
>D>	AB		2MG	N74826 002 Jul 03, 1997 Apr CAHN
>A>	AB	PAR PHARM	1MG	N74826 001 Jul 03, 1997 Apr CAHN
>A>	AB		2MG	N74826 002 Jul 03, 1997 Apr CAHN

ESTRADIOL

GEL; TOPICAL

ESTROGEL

@ ASCEND

0.06%

N21166 001 Feb 09, 2004 Jan CAHN

GEL, METERED; TOPICAL

ESTROGEL

+ ASCEND

0.06%

N21166 002 Feb 09, 2004 Jan CAHN

ESTRADIOL HEMIHYDRATE

EMULSION; TOPICAL

ESTRASORB

+ ESPRIT PHARMA

0.25%

N21371 001 Oct 09, 2003 Feb CAHN

ESTROGENS, CONJUGATED SYNTHETIC B

TABLET; ORAL

ENJUVIA

DURAMED

0.3MG

N21443 001 Dec 20, 2004 Mar CMFD

0.45MG

N21443 002 Dec 20, 2004 Mar CMFD

0.625MG

N21443 003 May 10, 2004 Mar CMFD

+

1.25MG

N21443 004 May 10, 2004 Mar CMFD

ETHINYLY ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

BALZIVA-21

BARR

0.035MG;0.4MG

N76198 001 Apr 22, 2004 Mar CRLD

TABLET; ORAL-28

OVCON-35

AB + WARNER CHILCOTT

0.035MG;0.4MG

N17716 001

Mar CRLD

ETHINYLY ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL

LOESTRIN 24 FE

+ WARNER CHILCOTT

0.02MG;1MG

N21871 001 Feb 17, 2006 Feb NEWA

ETODOLAC

CAPSULE; ORAL

ETODOLAC

@ ENDO PHARMS

200MG

N74842 001 Jul 17, 1997 Feb DISC

@

300MG

N74842 002 Jul 17, 1997 Feb DISC

AB + TARO

300MG

N75078 002 Apr 30, 1998 Mar CRLD

CAPSULE; ORAL

LODINE						
@ WYETH PHARMS INC	300MG			N18922	003	Jan 31, 1991 Mar DISC
TABLET; ORAL						
ETODOLAC						
@ ENDO PHARMS	400MG			N74841	001	Jun 27, 1997 Feb DISC

FENOFIBRATE

CAPSULE; ORAL

LIPOFEN						
CIPHER	50MG			N21612	001	Jan 11, 2006 Jan NEWA
	100MG			N21612	002	Jan 11, 2006 Jan NEWA
+	150MG			N21612	003	Jan 11, 2006 Jan NEWA

TABLET; ORAL

FENOFIBRATE

AB	+	TEVA	160MG		N76433	002	May 13, 2005 Jan CRLD
		TRICOR					
		@ ABBOTT	54MG		N21203	001	Sep 04, 2001 Jan DISC
		@	160MG		N21203	003	Sep 04, 2001 Jan DISC

FENOLDOPAM MESYLATE

INJECTABLE; INJECTION

FENOLDOPAM MESYLATE						
AP	SANDOZ	EQ 10MG BASE/ML		N77155	001	Feb 15, 2005 Jan CAHN

FENOPROFEN CALCIUM

TABLET; ORAL

FENOPROFEN CALCIUM						
@ CLONMEL HLTHCARE	EQ 600MG BASE			N72326	001	Aug 17, 1988 Jan DISC

FENTANYL CITRATE

TROCHE/LOZENGE; TRANSMUCOSAL

ACTIQ (SUGAR-FREE)

CEPHALON	EQ 0.2MG BASE			N20747	001	Nov 04, 1998 Mar CTNA
+	EQ 0.4MG BASE			N20747	002	Nov 04, 1998 Mar CTNA
	EQ 0.6MG BASE			N20747	003	Nov 04, 1998 Mar CTNA
	EQ 0.8MG BASE			N20747	004	Nov 04, 1998 Mar CTNA
	EQ 1.2MG BASE			N20747	005	Nov 04, 1998 Mar CTNA
	EQ 1.6MG BASE			N20747	006	Nov 04, 1998 Mar CTNA

FEXOFENADINE HYDROCHLORIDE

TABLET; ORAL

FEXOFENADINE HYDROCHLORIDE

AB	DR REDDYS LABS LTD	30MG		N76502	001	Apr 11, 2006 Mar NEWA
AB		60MG		N76502	002	Apr 11, 2006 Mar NEWA
AB		180MG		N76502	003	Apr 11, 2006 Mar NEWA

FLUCONAZOLE

TABLET; ORAL

FLUCONAZOLE

AB	GLENMARK PHARMA	50MG		N77253	001	Jan 25, 2006 Jan NEWA
AB		100MG		N77253	002	Jan 25, 2006 Jan NEWA
AB		150MG		N77253	003	Jan 25, 2006 Jan NEWA
AB		200MG		N77253	004	Jan 25, 2006 Jan NEWA

FLUMAZENIL

INJECTABLE; INJECTION

FLUMAZENIL

AP	SANDOZ	0.5MG/5ML (0.1MG/ML)	N77071 001 May 03, 2005 Jan CAHN
AP		1MG/10ML (0.1MG/ML)	N77071 002 May 03, 2005 Jan CAHN

FLUNISOLIDE

AEROSOL, METERED; INHALATION

AEROSPAN HFA

+ FOREST LABS EQ 78UGM BASE/INH

N21247 001 Jan 27, 2006 Jan NEWA

FLUORESCIN SODIUM

INJECTABLE; INTRAVENOUS

FLUORESCITE

+ ALCON RES EQ 500MG BASE/5ML (EQ 100MG
BASE/ML)

N21980 001 Mar 28, 2006 Mar NEWA

FLUOROURACIL

INJECTABLE; INJECTION

ADRUCIL

AP	+ SICOR PHARMS	50MG/ML	N40023 001 Oct 18, 1991 Mar CRLD
	FLUOROURACIL		
AP	+ AM PHARM PARTNERS	50MG/ML	N40278 001 Sep 30, 1998 Mar CRLD
AP	+	50MG/ML	N40279 001 Sep 30, 1998 Mar CRLD
AP	+	50MG/ML	N40291 001 Mar 24, 1999 Mar CRLD
AP	+	50MG/ML	N40379 001 Nov 15, 2000 Mar CRLD
>D>	AP + BEDFORD	50MG/ML	N89508 001 Jan 26, 1988 Apr DISC
>A>	@	50MG/ML	N89508 001 Jan 26, 1988 Apr DISC
	AP +	50MG/ML	N89508 001 Jan 26, 1988 Mar CRLD
	AP + SICOR PHARMS	50MG/ML	N40333 001 Jan 27, 2000 Mar CRLD
	AP +	50MG/ML	N40334 001 Feb 25, 2000 Mar CRLD
>D>	AP + STERIS	50MG/ML	N87792 001 Oct 13, 1982 Apr DISC
	AP +	50MG/ML	N87792 001 Oct 13, 1982 Mar CRLD
>A>	@ WATSON LABS	50MG/ML	N87792 001 Oct 13, 1982 Apr DISC

FLUPHENAZINE HYDROCHLORIDE

ELIXIR; ORAL

FLUPHENAZINE HYDROCHLORIDE

>D>	AA PHARM ASSOC	2.5MG/5ML	N40146 001 Aug 21, 1996 Apr CRLD
>A>	+	2.5MG/5ML	N40146 001 Aug 21, 1996 Apr CRLD
>D>	AA TEVA PHARMS	2.5MG/5ML	N81310 001 Apr 29, 1993 Apr DISC
>A>	@	2.5MG/5ML	N81310 001 Apr 29, 1993 Apr DISC
>D>	PROLIXIN		
>D>	AA + APOTHECON	2.5MG/5ML	N12145 003 Apr DISC
>A>	@	2.5MG/5ML	N12145 003 Apr DISC

FLUTAMIDE

CAPSULE; ORAL

FLUTAMIDE

>A>	AB PAR PHARM	125MG	N75298 001 Sep 18, 2001 Apr CAHN
>D>	AB TEVA	125MG	N75298 001 Sep 18, 2001 Apr CAHN

FLUTICASONE PROPIONATE

OINTMENT; TOPICAL
FLUTICASONE PROPIONATE

AB	G AND W LABS	0.005%	N77168 001 Mar 03, 2006 Feb NEWA
	SPRAY, METERED; NASAL FLONASE		
AB	+ GLAXOSMITHKLINE	0.05MG/SPRAY	N20121 001 Oct 19, 1994 Feb CFTG
	FLUTICASONE PROPIONATE		
AB	ROXANE	0.05MG/SPRAY	N76504 001 Feb 22, 2006 Feb NEWA

FLUVOXAMINE MALEATE

TABLET; ORAL
FLUVOXAMINE MALEATE

AB	CARACO	25MG	N75900 001 Feb 23, 2006 Feb NEWA
AB		50MG	N75900 002 Feb 23, 2006 Feb NEWA
AB		100MG	N75900 003 Feb 23, 2006 Feb NEWA

FOSCARNET SODIUM

INJECTABLE; INJECTION
FOSCARNET SODIUM

AP	HOSPIRA	2.4GM/100ML	N77174 001 May 31, 2005 Feb CAHN
----	---------	-------------	----------------------------------

GABAPENTIN

CAPSULE; ORAL
GABAPENTIN

AB	SANDOZ	100MG	N75428 001 Jan 24, 2006 Jan NEWA
AB		300MG	N75428 002 Jan 24, 2006 Jan NEWA
AB		400MG	N75428 003 Jan 24, 2006 Jan NEWA
	TABLET; ORAL GABAPENTIN		
AB	SANDOZ	600MG	N76120 001 Jan 27, 2006 Jan NEWA
AB		800MG	N76120 002 Jan 27, 2006 Jan NEWA

GADOVERSETAMIDE

INJECTABLE; INJECTION
OPTIMARK

+	MALLINCKRODT	1654.5MG/5ML (330.9MG/ML)	N20937 001 Dec 08, 1999 Jan CPOT
+		3309MG/10ML (330.9MG/ML)	N20937 002 Dec 08, 1999 Jan NEWA
+		4963.5MG/15ML (330.9MG/ML)	N20937 003 Dec 08, 1999 Jan NEWA
+		6618MG/20ML (330.9MG/ML)	N20937 004 Dec 08, 1999 Jan NEWA
+		16.545GM/50ML (330.9MG/ML)	N20975 001 Dec 08, 1999 Jan CPOT
	OPTIMARK IN PLASTIC CONTAINER		
+	MALLINCKRODT	1654.5MG/5ML (330.9MG/ML)	N20976 001 Dec 08, 1999 Jan CPOT
+		3309MG/10ML (330.9MG/ML)	N20976 002 Dec 08, 1999 Jan NEWA
+		4963.5MG/15ML (330.9MG/ML)	N20976 003 Dec 08, 1999 Jan NEWA
+		6618MG/20ML (330.9MG/ML)	N20976 004 Dec 08, 1999 Jan NEWA

GLIMEPIRIDE

TABLET; ORAL
GLIMEPIRIDE

AB	COBALT	1MG	N77280 001 Feb 03, 2006 Jan NEWA
AB		2MG	N77280 002 Feb 03, 2006 Jan NEWA
AB		4MG	N77280 003 Feb 03, 2006 Jan NEWA
AB	GENPHARM	1MG	N77486 001 Feb 10, 2006 Jan NEWA

TABLET; ORAL

GLIMEPIRIDE

AB	GENPHARM	2MG	N77486 002	Feb 10, 2006	Jan	NEWA
AB		4MG	N77486 003	Feb 10, 2006	Jan	NEWA

GLIPIZIDE

TABLET; ORAL

GLIPIZIDE

@ ENDO PHARMS	5MG	N74378 001	Nov 28, 1994	Feb	DISC
@	10MG	N74378 002	Nov 28, 1994	Feb	DISC

TABLET, EXTENDED RELEASE; ORAL

GLIPIZIDE

AB	WATSON LABS	2.5MG	N76467 003	Mar 27, 2006	Mar	NEWA
	GLUCOTROL XL					
AB	PFIZER	2.5MG	N20329 003	Aug 10, 1999	Mar	CFTG

GLYBURIDE

TABLET; ORAL

DIABETA

BX	+	SANOFI AVENTIS US	5MG	N17532 003	May 01, 1984	Feb	CRLD
----	---	-------------------	-----	------------	--------------	-----	------

HALOBETASOL PROPIONATE

CREAM; TOPICAL

HALOBETASOL PROPIONATE

>D>	AB	AGIS IND'S	0.05%	N77123 001	Dec 16, 2004	Apr	CAHN
>A>	AB	PERRIGO ISRAEL	0.05%	N77123 001	Dec 16, 2004	Apr	CAHN
		OINTMENT; TOPICAL					
		HALOBETASOL PROPIONATE					
AB		PERRIGO	0.05%	N76872 001	Dec 16, 2004	Mar	CAHN

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION

HALOPERIDOL DECANOATE

AO	SANDOZ	EQ 50MG BASE/ML	N76463 001	Jun 24, 2005	Jan	CAHN
AO		EQ 100MG BASE/ML	N76463 002	Jun 24, 2005	Jan	CAHN

HALOPERIDOL LACTATE

INJECTABLE; INJECTION

HALOPERIDOL

AP	SANDOZ	EQ 5MG BASE/ML	N76464 001	Sep 29, 2004	Jan	CAHN
----	--------	----------------	------------	--------------	-----	------

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL

APRESOLINE

@	NOVARTIS	10MG	N08303 004		Feb	DISC
@		25MG	N08303 001		Feb	DISC
@		50MG	N08303 002		Feb	DISC
@		100MG	N08303 005		Feb	DISC

HYDRALAZINE HYDROCHLORIDE

AA	+	PLIVA	10MG	N89097 001	Dec 18, 1985	Feb	CRLD
AA	+		25MG	N88467 001	May 01, 1984	Feb	CRLD
AA	+		50MG	N88468 001	May 01, 1984	Feb	CRLD
AA	+		100MG	N89098 001	Dec 18, 1985	Feb	CRLD

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET; ORAL

LISINOPRIL AND HYDROCHLOROTHIAZIDE

AB	AUROBINDO	12.5MG;10MG	N77606 001 Mar 14, 2006 Feb NEWA
AB		12.5MG;20MG	N77606 002 Mar 14, 2006 Feb NEWA
AB		25MG;20MG	N77606 003 Mar 14, 2006 Feb NEWA

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

DIOVAN HCT

>A>	NOVARTIS	12.5MG;320MG	N20818 004 Apr 28, 2006 Apr NEWA
>D>	+	25MG;160MG	N20818 003 Jan 17, 2002 Apr CRLD
>A>		25MG;160MG	N20818 003 Jan 17, 2002 Apr CRLD
>A>	+	25MG;320MG	N20818 005 Apr 28, 2006 Apr NEWA

HYDROCORTISONE SODIUM SUCCINATE

INJECTABLE; INJECTION

A-HYDROCORT

AP	HOSPIRA	EQ 100MG BASE/VIAL	N40666 001 Apr 06, 2006 Mar NEWA
----	---------	--------------------	----------------------------------

HYDROCORTISONE; NEOMYCIN; POLYMYXIN B SULFATE

SUSPENSION/DROPS; OTIC

NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

>A>	AT	PHARMAFORCE	1%;EQ 3.5MG BASE;10,000 UNITS	N65219 001 May 01, 2006 Apr NEWA
-----	----	-------------	-------------------------------	----------------------------------

HYDROXYZINE PAMOATE

CAPSULE; ORAL

HYDROXYZINE PAMOATE

BARR		EQ 100MG HCL	N88488 001 Jun 15, 1984 Mar CTEC
VISTARIL @ PFIZER		EQ 100MG HCL	N11459 006 Mar DISC

IBANDRONATE SODIUM

INJECTABLE; INTRAVENOUS

BONIVA

+ ROCHE		EQ 3MG BASE/3ML	N21858 001 Jan 06, 2006 Jan NEWA
---------	--	-----------------	----------------------------------

IBUPROFEN LYSINE

>A>		INJECTABLE; INTRAVENOUS	
>A>		NEOPROFEN	
>A>	+	FARMACON IL	EQ 20MG BASE/2ML (EQ 10MG BASE/ML) N21903 001 Apr 13, 2006 Apr NEWA

INDOMETHACIN

SUPPOSITORY; RECTAL

INDOMETHACIN

>A>	+	G AND W LABS	50MG N73314 001 Aug 31, 1992 Apr CTNA
>D>		INDOMETHEGAN	
>D>	+	G AND W LABS	50MG N73314 001 Aug 31, 1992 Apr CTNA

INSULIN GLULISINE RECOMBINANT

INJECTABLE; SUBCUTANEOUS

APIDRA

+ SANOFI AVENTIS US		1000 UNITS/10ML (100 UNITS/ML)	N21629 001 Apr 16, 2004 Mar CMFD
+		300 UNITS/3ML (100 UNITS/ML)	N21629 002 Dec 20, 2005 Mar CMFD

INSULIN RECOMBINANT HUMAN

POWDER; INHALATION						
EXUBERA						
PFIZER	1MG/INH					N21868 001 Jan 27, 2006 Jan NEWA
+	3MG/INH					N21868 002 Jan 27, 2006 Jan NEWA

ISONIAZID

INJECTABLE; INJECTION						
ISONIAZID						
AP SANDOZ	100MG/ML					N40648 001 Jul 05, 2005 Jan CAHN

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE; ORAL						
ISOSORBIDE MONONITRATE						
AB WEST WARD	30MG					N76813 002 Mar 30, 2006 Mar NEWA

ISRADIPINE

CAPSULE; ORAL						
ISRADIPINE						
>D> ABRIKA PHARMS	5MG					N77317 002 Jan 05, 2006 Apr CTEC
>A> AB	5MG					N77317 002 Jan 05, 2006 Apr CTEC
>A> AB AMIDE PHARM	2.5MG					N77169 001 Apr 24, 2006 Apr NEWA
>A> AB	5MG					N77169 002 Apr 24, 2006 Apr NEWA

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION						
KETOROLAC TROMETHAMINE						
AP SANDOZ	15MG/ML					N76271 001 Oct 06, 2004 Jan CAHN
AP	30MG/ML					N76271 002 Oct 06, 2004 Jan CAHN

KETOTIFEN FUMARATE

SOLUTION/DROPS; OPHTHALMIC						
>A> KETOTIFEN FUMARATE						
>A> AT APOTEX	EQ 0.025% BASE					N77354 001 May 09, 2006 Apr NEWA
ZADITOR						
>D> + NOVARTIS	EQ 0.025% BASE					N21066 001 Jul 02, 1999 Apr CFTG
>A> AT +	EQ 0.025% BASE					N21066 001 Jul 02, 1999 Apr CFTG

LANSOPRAZOLE; NAPROXEN

CAPSULE, DELAYED REL PELLETS, TABLET; ORAL						
PREVACID NAPRAPAC 250 (COPACKAGED)						
TAP PHARM	15MG,N/A;N/A,250MG					N21507 002 Nov 14, 2003 Feb CTNA
PREVACID NAPRAPAC 375 (COPACKAGED)						
TAP PHARM	15MG,N/A;N/A,375MG					N21507 003 Nov 14, 2003 Feb CTNA
PREVACID NAPRAPAC 500 (COPACKAGED)						
+ TAP PHARM	15MG,N/A;N/A,500MG					N21507 004 Nov 14, 2003 Feb CTNA

LEVETIRACETAM

TABLET; ORAL						
KEPPRA						
UCB INC	750MG					N21035 003 Nov 30, 1999 Mar CRLD
+	1GM					N21035 004 Jan 06, 2006 Mar NEWA

LEVOBETAXOLOL HYDROCHLORIDE

SUSPENSION/DROPS; OPHTHALMIC
 BETAXON
 @ ALCON EQ 0.5% BASE N21114 001 Feb 23, 2000 Feb CAHN

LIDOCAINE HYDROCHLORIDE

JELLY; TOPICAL
 ANESTACON
 AT + POLYMEDICA 2% N80429 001 Jan CDFR

LIDOCAINE; TETRACAIN

PATCH; TOPICAL
 SYNERA
 + ENDO PHARMS 70MG;70MG N21623 001 Jun 23, 2005 Feb CAHN

LISINOPRIL

TABLET; ORAL
 LISINOPRIL
 AB AUROBINDO 2.5MG N77622 001 Feb 22, 2006 Feb NEWA
 AB 5MG N77622 002 Feb 22, 2006 Feb NEWA
 AB 10MG N77622 003 Feb 22, 2006 Feb NEWA
 AB 20MG N77622 004 Feb 22, 2006 Feb NEWA
 AB 30MG N77622 005 Feb 22, 2006 Feb NEWA
 AB 40MG N77622 006 Feb 22, 2006 Feb NEWA

LORAZEPAM

TABLET; ORAL
 LORAZEPAM
 AB MYLAN 0.5MG N77657 001 Mar 16, 2006 Mar NEWA
 AB 1MG N77657 002 Mar 16, 2006 Mar NEWA
 AB 2MG N77657 003 Mar 16, 2006 Mar NEWA
 >A> AB VINTAGE PHARMS 0.5MG N77754 001 May 10, 2006 Apr NEWA
 >A> AB 1MG N77754 002 May 10, 2006 Apr NEWA
 >A> AB 2MG N77754 003 May 10, 2006 Apr NEWA

LOVASTATIN

TABLET; ORAL
 LOVASTATIN
 >A> AB MUTUAL PHARM 10MG N77520 001 Apr 14, 2006 Apr NEWA
 >A> AB 20MG N77520 002 Apr 14, 2006 Apr NEWA
 >A> AB 40MG N77520 003 Apr 14, 2006 Apr NEWA

LOVASTATIN; NIACIN

TABLET, EXTENDED RELEASE; ORAL
 ADVICOR
 + KOS LIFE 20MG;750MG N21249 002 Dec 17, 2001 Feb CMFD

LUBIPROSTONE

CAPSULE; ORAL
 AMITIZA
 + SUCAMPO PHARMS 24UGM N21908 001 Jan 31, 2006 Jan NEWA

MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE

TABLET, CHEWABLE; ORAL

ZEGERID

SANTARUS	700MG;20MG;600MG	N21850 001 Mar 24, 2006 Mar NEWA
+	700MG;40MG;600MG	N21850 002 Mar 24, 2006 Mar NEWA

MEDROXYPROGESTERONE ACETATE

INJECTABLE; SUBCUTANEOUS

DEPO-SUBQ PROVERA 104

+ PHARMACIA AND UPJOHN	104MG/0.65ML	N21583 001 Dec 17, 2004 Jan CAHN
------------------------	--------------	----------------------------------

MEGESTROL ACETATE

SUSPENSION; ORAL

MEGESTROL ACETATE

AB APOTEX	40MG/ML	N77404 001 Feb 16, 2006 Jan NEWA
-----------	---------	----------------------------------

MEPROBAMATE

TABLET; ORAL

MEPROBAMATE

@ ROXANE	600MG	N84332 001 Jan DISC
@ SANDOZ	200MG	N14547 002 Jan DISC
@	400MG	N14547 001 Jan DISC
@	400MG	N80655 001 Jan DISC
@ SCHERER LABS	400MG	N83343 001 Jan DISC
@ TABLICAPS	400MG	N83494 001 Jan DISC
AA + WATSON LABS	200MG	N83304 001 Jan CRLD
@	200MG	N85720 001 Jan DISC
+	400MG	N83308 001 Jan CRLD
@	400MG	N85721 001 Jan DISC
MILTOWN		
@ MEDPOINTE PHARM HLC	200MG	N09698 004 Jan DISC
@	400MG	N09698 002 Jan DISC
TRANMEP		
@ SOLVAY	400MG	N16249 001 Jan DISC

MESALAMINE

ENEMA; RECTAL

ROWASA

>A> AB + ALAVEN PHARM	4GM/60ML	N19618 001 Dec 24, 1987 Apr CAHN
>D> AB + SOLVAY	4GM/60ML	N19618 001 Dec 24, 1987 Apr CAHN

METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

GLUMETZA

BX DEPOMED INC	500MG	N21748 001 Jun 03, 2005 Jan CAHN
BX	1GM	N21748 002 Jun 03, 2005 Jan CAHN
METFORMIN HYDROCHLORIDE		
AB SUN PHARM IND (IN)	500MG	N77336 001 Feb 09, 2006 Jan NEWA
AB	750MG	N77336 002 Feb 09, 2006 Jan NEWA

METHOTREXATE

INJECTABLE; INJECTION

METHOTREXATE PRESERVATIVE FREE

>D> + BEDFORD	EQ 1GM BASE/VIAL	N40632 001 Aug 12, 2005 Apr CAIN
---------------	------------------	----------------------------------

>A>	<u>METHOTREXATE SODIUM</u>		
>A>	INJECTABLE; INJECTION		
>A>	METHOTREXATE PRESERVATIVE FREE		
>A>	+ BEDFORD	EQ 1GM BASE/VIAL	N40632 001 Aug 12, 2005 Apr CAIN
>D> AP	+ MAYNE PHARMA USA	ED 1GM BASE/40ML (25 MG/ML)	N11719 012 Apr 13, 2005 Apr CPOT
>A>	+	EQ 1GM BASE/40ML (25 MG/ML)	N11719 012 Apr 13, 2005 Apr CPOT
	METHOTREXATE SODIUM		
>D> AP	BEDFORD	EQ 50 MG BASE/2ML (25 ML/ML)	N89340 001 Sep 16, 1986 Apr CPOT
>A> AP	+	EQ 50MG BASE/2ML (25MG/ML)	N89340 001 Sep 16, 1986 Apr CPOT
>D> AP		EQ 100MG BASE/4ML (25 MG/ML)	N89341 001 Sep 16, 1986 Apr CTEC
>A>	+	EQ 100MG BASE/4ML (25 MG/ML)	N89341 001 Sep 16, 1986 Apr CTEC
>D> AP		EQ 200MG BASE/8ML (25 MG/ML)	N89342 001 Sep 16, 1986 Apr CTEC
>A>	+	EQ 200MG BASE/8ML (25 MG/ML)	N89342 001 Sep 16, 1986 Apr CTEC
>D> AP		EQ 250MG BASE/10ML (25 MG/ML)	N89343 001 Sep 16, 1986 Apr CTEC
>A>	+	EQ 250MG BASE/10ML (25 MG/ML)	N89343 001 Sep 16, 1986 Apr CTEC
	<u>METHYLPHENIDATE</u>		
>A>	FILM, EXTENDED RELEASE; TRANSDERMAL		
>A>	DAYTRANA		
>A>	+ SHIRE	10MG/9HR (1.1MG/HR)	N21514 001 Apr 06, 2006 Apr NEWA
>A>	+	15MG/9HR (1.6MG/HR)	N21514 002 Apr 06, 2006 Apr NEWA
>A>	+	20MG/9HR (2.2MG/HR)	N21514 003 Apr 06, 2006 Apr NEWA
>A>	+	30MG/9HR (3.3MG/HR)	N21514 004 Apr 06, 2006 Apr NEWA
	<u>METHYLPHENIDATE HYDROCHLORIDE</u>		
	CAPSULE, EXTENDED RELEASE; ORAL		
	METADATE CD		
BX	UCB INC	40MG	N21259 004 Feb 19, 2006 Feb NEWA
		50MG	N21259 005 Feb 19, 2006 Feb NEWA
	+	60MG	N21259 006 Feb 19, 2006 Feb NEWA
	RITALIN LA		
BX	+ NOVARTIS	40MG	N21284 003 Jun 05, 2002 Feb CTEC
	<u>METOCLOPRAMIDE HYDROCHLORIDE</u>		
	TABLET; ORAL		
	METOCLOPRAMIDE HYDROCHLORIDE		
>D>	@ MUTUAL PHARM	EQ 5MG BASE	N71536 002 Jan 16, 1997 Apr CMFD
>A> AB		EQ 5MG BASE	N71536 002 Jan 16, 1997 Apr CMFD
>D>	@	EQ 10MG BASE	N71536 001 Apr 28, 1993 Apr CMFD
>A> AB		EQ 10MG BASE	N71536 001 Apr 28, 1993 Apr CMFD
	<u>MICONAZOLE NITRATE; PETROLATUM, WHITE; ZINC OXIDE</u>		
	OINTMENT; TOPICAL		
	VUSION		
	+ BARRIER	0.25%;81.35%;15%	N21026 001 Feb 16, 2006 Feb NEWA
	<u>MIDAZOLAM HYDROCHLORIDE</u>		
	INJECTABLE; INJECTION		
	MIDAZOLAM HYDROCHLORIDE		
AP	+ HOSPIRA	EQ 5MG BASE/ML	N75293 002 Jun 20, 2000 Mar CRLD

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL						
MINOCIN						
AB TRIAX PHARMS	EQ 50MG BASE		N50649	001	May 31, 1990	Feb CAHN
@	EQ 75MG BASE		N50649	003	Feb 12, 2001	Feb CAHN
AB +	EQ 100MG BASE		N50649	002	May 31, 1990	Feb CAHN

MIRTAZAPINE

TABLET, ORALLY DISINTEGRATING; ORAL						
MIRTAZAPINE						
AB AUROBINDO PHARMA LTD	45MG		N77376	004	Feb 28, 2006	Feb NEWA
AB BARR	45MG		N76307	003	Feb 28, 2006	Feb NEWA

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION						
MITOXANTRONE						
AP AM PHARM	EQ 20MG BASE/10ML (2MG/ML)		N77496	001	Apr 11, 2006	Mar NEWA
AP	EQ 25MG BASE/12.5ML (2MG/ML)		N77496	002	Apr 11, 2006	Mar NEWA
AP	EQ 30MG BASE/15ML (2MG/ML)		N77496	003	Apr 11, 2006	Mar NEWA
AP BEDFORD	EQ 20MG BASE/10ML (2MG/ML)		N76611	001	Apr 11, 2006	Mar NEWA
AP	EQ 25MG BASE/12.5ML (2MG/ML)		N76611	002	Apr 11, 2006	Mar NEWA
AP	EQ 30MG BASE/15ML (2MG/ML)		N76611	003	Apr 11, 2006	Mar NEWA
AP MAYNE PHARMA USA	EQ 20MG BASE/10ML (2MG/ML)		N76871	001	Apr 11, 2006	Mar NEWA
AP	EQ 25MG BASE/12.5ML (2MG/ML)		N76871	002	Apr 11, 2006	Mar NEWA
AP	EQ 30MG BASE/15ML (2MG/ML)		N76871	003	Apr 11, 2006	Mar NEWA
AP SICOR PHARMS	EQ 20MG BASE/10ML (2MG/ML)		N77356	001	Apr 11, 2006	Mar NEWA
AP	EQ 25MG BASE/12.5ML (2MG/ML)		N77356	002	Apr 11, 2006	Mar NEWA
AP	EQ 30MG BASE/15ML (2MG/ML)		N77356	003	Apr 11, 2006	Mar NEWA
NOVANTRONE						
AP + SERONO INC	EQ 20MG BASE/10ML(2MG/ML)		N19297	001	Dec 23, 1987	Mar CFTG
AP +	EQ 25MG BASE/12.5ML (2MG/ML)		N19297	002	Dec 23, 1987	Mar CFTG
AP +	EQ 30MG BASE/15ML (2MG/ML)		N19297	003	Dec 23, 1987	Mar CFTG

MOMETASONE FUROATE

LOTION; TOPICAL						
MOMETASONE FUROATE						
AB PERRIGO	0.1%		N77180	001	Apr 06, 2005	Mar CAHN
AB TARO	0.1%		N76788	001	Mar 15, 2006	Feb NEWA

MORPHINE SULFATE

INJECTABLE; INJECTION						
MORPHINE SULFATE						
HOSPIRA	5MG/ML		N19916	002	Mar 30, 2006	Mar NEWA

NABUMETONE

TABLET; ORAL						
NABUMETONE						
>D> AB IVAX PHARMS	500MG		N76009	001	Jan 24, 2003	Apr CAHN
>D> AB	750MG		N76009	002	Jan 24, 2003	Apr CAHN
>A> AB PAR PHARM	500MG		N76009	001	Jan 24, 2003	Apr CAHN
>A> AB	750MG		N76009	002	Jan 24, 2003	Apr CAHN

NAFCILLIN SODIUM

INJECTABLE; INJECTION

NAFCILLIN SODIUM

>D>	AP	SANDOZ	EQ 1GM BASE/VIAL	N62527	002	Aug 02, 1984	Apr	CRLD
>A>	AP	+	EQ 1GM BASE/VIAL	N62527	002	Aug 02, 1984	Apr	CRLD
>D>	AP		EQ 1GM BASE/VIAL	N62732	001	Dec 23, 1986	Apr	CRLD
>A>	AP	+	EQ 1GM BASE/VIAL	N62732	001	Dec 23, 1986	Apr	CRLD
>D>	AP		EQ 2GM BASE/VIAL	N62527	003	Aug 02, 1984	Apr	CRLD
>A>	AP	+	EQ 2GM BASE/VIAL	N62527	003	Aug 02, 1984	Apr	CRLD
>D>	AP		EQ 2GM BASE/VIAL	N62732	002	Dec 23, 1986	Apr	CRLD
>A>	AP	+	EQ 2GM BASE/VIAL	N62732	002	Dec 23, 1986	Apr	CRLD
>D>	AP		EQ 10GM BASE/VIAL	N62527	004	Aug 02, 1984	Apr	CRLD
>A>	AP	+	EQ 10GM BASE/VIAL	N62527	004	Aug 02, 1984	Apr	CRLD

NALTREXONE

>A>	FOR SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR		
>A>	VIVITROL		
>A>	+	ALKERMES	380MG/VIAL

N21897 001 Apr 13, 2006 Apr NEWA

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION; IRRIGATION

NEOSPORIN AND POLYMYXIN B SULFATE

AT	X GEN PHARMS	EQ 40MG BASE/ML;200,000 UNITS/ML	N65106	001	Jan 31, 2006	Jan	NEWA
AT		EQ 800MG BASE/20ML;4,000,000 UNITS/20ML (EQ 40MG BASE/ML;200,000 UNITS/ML)	N65108	001	Jan 31, 2006	Jan	NEWA
	NEOSPORIN G.U. IRRIGANT						
AT	+	MONARCH PHARMS	EQ 40MG BASE/ML;200,000 UNITS/ML	N60707	001	Jan	CTEC
AT	+		EQ 800MG BASE/20ML;4,000,000 UNITS/20ML (EQ 40MG BASE/ML;200,000 UNITS/ML)	N60707	002	Jan	NEWA

NICARDIPINE HYDROCHLORIDE

CAPSULE; ORAL

NICARDIPINE HYDROCHLORIDE

>A>	AB	BARR	20MG	N74439	001	Dec 10, 1996	Apr	CAHN
>A>	AB		30MG	N74439	002	Dec 10, 1996	Apr	CAHN
>D>	AB	IVAX PHARMS	20MG	N74439	001	Dec 10, 1996	Apr	CAHN
>D>	AB		30MG	N74439	002	Dec 10, 1996	Apr	CAHN
	INJECTABLE; INJECTION							
	CARDENE							
	+	PDL BIOPHARMA INC	2.5MG/ML	N19734	001	Jan 30, 1992	Jan	CAHN

NIFEDIPINE

TABLET, EXTENDED RELEASE; ORAL

AFEDITAB CR

AB1	WATSON LABS	30MG	N75128	001	Mar 10, 2000	Jan	CAHN
AB1		60MG	N75659	001	Oct 26, 2001	Jan	CAHN

OCTREOTIDE ACETATE

INJECTABLE; INJECTION

OCTREOTIDE ACETATE

AP	AM PHARM	EQ 0.2MG BASE/ML	N77450	001	Feb 10, 2006	Jan	NEWA
AP		EQ 1MG BASE/ML	N77450	002	Feb 10, 2006	Jan	NEWA
	OCTREOTIDE ACETATE (PRESERVATIVE FREE)						
AP	AM PHARM	EQ 0.05MG BASE/ML	N77457	001	Feb 10, 2006	Jan	NEWA

INJECTABLE; INJECTION

OCTREOTIDE ACETATE (PRESERVATIVE FREE)

AP	AM PHARM	EQ 0.1MG BASE/ML	N77457 002	Feb 10, 2006	Jan	NEWA
AP		EQ 0.5MG BASE/ML	N77457 003	Feb 10, 2006	Jan	NEWA

OFLOXACIN

TABLET; ORAL

OFLOXACIN

AB	DR REDDYS LABS LTD	200MG	N77098 001	Feb 10, 2006	Jan	NEWA
AB		300MG	N77098 002	Feb 10, 2006	Jan	NEWA
AB		400MG	N77098 003	Feb 10, 2006	Jan	NEWA

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE; ORAL

ZEGERID

	SANTARUS	20MG;1.1GM	N21849 001	Feb 27, 2006	Feb	NEWA
+		40MG;1.1GM	N21849 002	Feb 27, 2006	Feb	NEWA

FOR SUSPENSION; ORAL

ZEGERID

	SANTARUS	20MG/PACKET;1.68GM/PACKET	N21636 001	Jun 15, 2004	Feb	CAIN
+		40MG/PACKET;1.68GM/PACKET	N21706 001	Dec 21, 2004	Feb	CAIN

OXYMETHOLONE

TABLET; ORAL

ANADROL-50

>A>	+	ALAVEN PHARM	50MG	N16848 001	Apr	CAHN
>D>	+	UNIMED PHARMS	50MG	N16848 001	Apr	CAHN

PACLITAXEL

FOR SUSPENSION; IV (INFUSION)

ABRAXANE

>A>	+	ABRAXIS BIOSCIENCE	100MG/VIAL	N21660 001	Jan 07, 2005	Apr	CAHN
>D>	+	AM BIOSCIENCE	100MG/VIAL	N21660 001	Jan 07, 2005	Apr	CAHN

PAROXETINE MESYLATE

TABLET; ORAL

PEXEVA

>A>		JDS PHARMS	EQ 10MG BASE	N21299 001	Jul 03, 2003	Apr	CAHN
>A>			EQ 20MG BASE	N21299 002	Jul 03, 2003	Apr	CAHN
>A>			EQ 30MG BASE	N21299 003	Jul 03, 2003	Apr	CAHN
>A>	+		EQ 40MG BASE	N21299 004	Jul 03, 2003	Apr	CAHN
>D>		SYNTTHON PHARMS	EQ 10MG BASE	N21299 001	Jul 03, 2003	Apr	CAHN
>D>			EQ 20MG BASE	N21299 002	Jul 03, 2003	Apr	CAHN
>D>			EQ 30MG BASE	N21299 003	Jul 03, 2003	Apr	CAHN
>D>	+		EQ 40MG BASE	N21299 004	Jul 03, 2003	Apr	CAHN

PENICILLIN V POTASSIUM

FOR SOLUTION; ORAL

PENICILLIN V POTASSIUM

AA	AM ANTIBIOTICS	EQ 125MG BASE/5ML	N61529 001	Jan	CAHN
AA		EQ 250MG BASE/5ML	N61529 002	Jan	CAHN

TABLET; ORAL

PENICILLIN V POTASSIUM

@	AM ANTIBIOTICS	EQ 250MG BASE	N61528 001	Jan	CAHN
@		EQ 500MG BASE	N61528 002	Jan	CAHN

PERGOLIDE MESYLATE

TABLET; ORAL

PERGOLIDE MESYLATE

>A>	AB	PAR PHARM	EQ 0.05MG BASE	N76061 001 Nov 27, 2002 Apr CAHN
>A>	AB		EQ 0.25MG BASE	N76061 002 Nov 27, 2002 Apr CAHN
>A>	AB		EQ 1MG BASE	N76061 003 Nov 27, 2002 Apr CAHN
>D>	AB	TEVA	EQ 0.05MG BASE	N76061 001 Nov 27, 2002 Apr CAHN
>D>	AB		EQ 0.25MG BASE	N76061 002 Nov 27, 2002 Apr CAHN
>D>	AB		EQ 1MG BASE	N76061 003 Nov 27, 2002 Apr CAHN
		PERMAX		
AB		VALEANT	EQ 0.05MG BASE	N19385 001 Dec 30, 1988 Jan CRLD
AB	+		EQ 0.25MG BASE	N19385 002 Dec 30, 1988 Jan CRLD

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETH VC PLAIN

+ ALPHARMA US PHARMS	5MG/5ML; 6.25MG/5ML	N88761 001 Nov 08, 1984 Jan CTEC
PROMETHAZINE VC PLAIN © MORTON GROVE	5MG/5ML; 6.25MG/5ML	N88897 001 Jan 04, 1985 Jan DISC

PHYTONADIONE

INJECTABLE; INJECTION

AQUAMEPHYTON

@ MERCK	1MG/0.5ML	N12223 002 Feb DISC
@	10MG/ML	N12223 001 Feb DISC
VITAMIN K1		
BP + HOSPIRA	1MG/0.5ML	N87954 001 Jul 25, 1983 Feb CRLD
+	10MG/ML	N87955 001 Jul 25, 1983 Feb CRLD

PILOCARPINE HYDROCHLORIDE

TABLET; ORAL

PILOCARPINE HYDROCHLORIDE

AB IMPAX LABS	5MG	N77248 001 Mar 31, 2006 Mar NEWA
AB	7.5MG	N77248 002 Mar 31, 2006 Mar NEWA
SALAGEN		
AB + MGI PHARMA INC	7.5MG	N20237 002 Apr 18, 2003 Mar CFTG

POLYETHYLENE GLYCOL 3350

FOR SOLUTION; ORAL

POLYETHYLENE GLYCOL 3350

>A> AA TEVA PHARMS	17GM/SCOOPFUL	N77445 001 May 04, 2006 Apr NEWA
--------------------	---------------	----------------------------------

POTASSIUM CHLORIDE

TABLET, EXTENDED RELEASE; ORAL

KLOR-CON

AB UPSHER SMITH	8MEQ	N19123 001 Apr 17, 1986 Jan CRLD
POTASSIUM CHLORIDE		

AB + COPLEY PHARM	8MEQ	N70618 001 Sep 09, 1987 Jan CRLD
-------------------	------	----------------------------------

PRAVASTATIN SODIUM

TABLET; ORAL

PRAVACHOL

>D> BRISTOL MYERS SQUIBB	10MG	N19898 002 Oct 31, 1991 Apr CFTG
>A> AB	10MG	N19898 002 Oct 31, 1991 Apr CFTG

TABLET; ORAL

PRAVACHOL

>D>	BRISTOL MYERS SQUIBB	20MG	N19898 003	Oct 31, 1991	Apr	CFTG
>A> AB		20MG	N19898 003	Oct 31, 1991	Apr	CFTG
>D>		40MG	N19898 004	Mar 22, 1993	Apr	CFTG
>A> AB		40MG	N19898 004	Mar 22, 1993	Apr	CFTG
>A>	PRAVASTATIN SODIUM					
>A> AB	TEVA	10MG	N76056 001	Apr 24, 2006	Apr	NEWA
>A> AB		20MG	N76056 002	Apr 24, 2006	Apr	NEWA
>A> AB		40MG	N76056 003	Apr 24, 2006	Apr	NEWA

PRAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

PRAZOSIN HYDROCHLORIDE

@ CLONMEL HLTHCARE	EQ 1MG BASE	N72705 001	May 16, 1989	Jan	DISC
@	EQ 5MG BASE	N72707 001	May 16, 1989	Jan	DISC

PREDNISOLONE ACETATE

INJECTABLE; INJECTION

PREDNISOLONE ACETATE

@ STERIS	25MG/ML	N83398 001	Mar	DISC
@	50MG/ML	N83764 001	Mar	DISC

PROMETHAZINE HYDROCHLORIDE

SUPPOSITORY; RECTAL

PHENERGAN

@ WYETH PHARMS INC	12.5MG	N10926 002	Mar	DISC
@	25MG	N10926 001	Mar	DISC

PROMETHAZINE HYDROCHLORIDE

AB + G AND W LABS	25MG	N40428 001	Feb 05, 2002	Mar	CRLD
-------------------	------	------------	--------------	-----	------

PROMETHEGAN

+ G AND W LABS	50MG	N87165 001	Aug 14, 1987	Jan	CRLD
----------------	------	------------	--------------	-----	------

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE

>A> AA VINTAGE	6.25MG/5ML	N40643 001	Apr 26, 2006	Apr	NEWA
----------------	------------	------------	--------------	-----	------

PROPOFOL

INJECTABLE; INJECTION

PROPOFOL

AB HOSPIRA	10MG/ML	N77908 001	Mar 17, 2006	Mar	NEWA
------------	---------	------------	--------------	-----	------

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

PROPOXYPHENE HYDROCHLORIDE

AA PAR PHARM	65MG	N80269 001	Mar	CAHN
--------------	------	------------	-----	------

PROPRANOLOL HYDROCHLORIDE

INJECTABLE; INJECTION

PROPRANOLOL HYDROCHLORIDE

AP SANDOZ	1MG/ML	N76400 001	Feb 26, 2003	Jan	CAHN
-----------	--------	------------	--------------	-----	------

PYRIDOSTIGMINE BROMIDE

INJECTABLE; INJECTION

REGONOL

AP SANDOZ	5MG/ML	N17398 001	Jan	CAHN
-----------	--------	------------	-----	------

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE

AB	TORPHARM	EQ 5MG BASE	N76240 001 Jan 26, 2006 Jan NEWA
AB		EQ 10MG BASE	N76240 002 Jan 26, 2006 Jan NEWA
AB		EQ 20MG BASE	N76240 003 Jan 26, 2006 Jan NEWA
AB		EQ 40MG BASE	N76240 004 Jan 26, 2006 Jan NEWA

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE; ORAL

QUINIDINE GLUCONATE

BX	+ MUTUAL PHARM	324MG	N89338 001 Feb 11, 1987 Jan CTEC
BX	WATSON LABS	324MG	N87810 001 Sep 29, 1982 Jan CMFD

QUINIDINE SULFATE

TABLET; ORAL

QUINIDINE SULFATE

@	CLONMEL HLTHCARE	200MG	N87011 001 Jan DISC
@	LANNETT	200MG	N83743 001 Jan DISC
@	MUTUAL PHARM	100MG	N81029 001 Apr 14, 1989 Jan DISC
@	PHARM FORM	200MG	N83808 001 Jan DISC
@	SANDOZ	200MG	N84631 001 Jan DISC
@		200MG	N84914 001 Jan DISC
AB		200MG	N88072 002 Jan NEWA
@		300MG	N89839 001 Sep 29, 1988 Jan DISC
@	WATSON LABS	200MG	N83288 001 Jan DISC
@		200MG	N85140 002 Jan DISC

RANITIDINE

INJECTABLE; INJECTION

RANITIDINE

AP	BEDFORD	EQ 25MG BASE/ML	N77458 001 Feb 16, 2006 Feb NEWA
----	---------	-----------------	----------------------------------

RANOLAZINE

TABLET, EXTENDED RELEASE; ORAL

RANEXA

+	CV THERAP	500MG	N21526 002 Jan 27, 2006 Jan NEWA
---	-----------	-------	----------------------------------

RISPERIDONE

TABLET, ORALLY DISINTEGRATING; ORAL

RISPERDAL

JANSSEN PHARMA	3MG	N21444 004 Dec 23, 2004 Mar CMFD
	4MG	N21444 005 Dec 23, 2004 Mar CMFD

SELEGILINE

FILM, EXTENDED RELEASE; TRANSDERMAL

EMSAM

SOMERSET	6MG/24HR	N21336 001 Feb 27, 2006 Mar CAIN
	9MG/24HR	N21336 002 Feb 27, 2006 Mar CAIN
+	12MG/24HR	N21336 003 Feb 27, 2006 Mar CAIN

SELEGILINE HYDROCHLORIDE

FILM, EXTENDED RELEASE; TRANSDERMAL EMSAM					
SOMERSET	6MG/24HR	N21336 001	Feb 27, 2006	Feb	NEWA
	9MG/24HR	N21336 002	Feb 27, 2006	Feb	NEWA
+	12MG/24HR	N21336 003	Feb 27, 2006	Feb	NEWA

SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

TABLET; ORAL OSMOPREP					
+ SALIX PHARMS	0.398GM;1.102GM	N21892 001	Mar 16, 2006	Mar	NEWA

SPIRONOLACTONE

TABLET; ORAL SPIRONOLACTONE					
AB PUREPAC PHARM	25MG	N40353 003	Mar 15, 2006	Feb	NEWA

SUCCINYLCHOLINE CHLORIDE

INJECTABLE; INJECTION ANECTINE				
AP + SANDOZ	20MG/ML	N08453 002	Jan	CAHN
@	50MG/ML	N08453 003	Jan	CAHN
@	500MG/VIAL	N08453 001	Jan	CAHN
@	1GM/VIAL	N08453 004	Jan	CAHN

SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC SULFACETAMIDE SODIUM					
>A> AT ALCON	30%	N89068 001	May 05, 1987	Apr	CAHN
>D> AT STERIS	30%	N89068 001	May 05, 1987	Apr	CAHN

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION; ORAL BACTRIM PEDIATRIC				
>D> @ MUTUAL PHARM	200MG/5ML;40MG/5ML	N17560 002	Apr	CMFD
>A> AB	200MG/5ML;40MG/5ML	N17560 002	Apr	CMFD

SUMATRIPTAN SUCCINATE

INJECTABLE; SUBCUTANEOUS IMITREX					
+ GLAXOSMITHKLINE	EQ 6MG BASE/0.5ML (12MG/ML)	N20080 001	Dec 28, 1992	Feb	CDFR
IMITREX STATDOSE					
+ GLAXOSMITHKLINE	EQ 4MG BASE/0.5ML (8MG/ML)	N20080 002	Feb 01, 2006	Feb	NEWA
+ GLAXOSMITHKLINE	EQ 6MG BASE/0.5ML (12MG/ML)	N20080 003	Dec 23, 1996	Feb	NEWA

SUNITINIB MALATE

CAPSULE; ORAL SUTENT					
PFIZER	12.5MG	N21938 001	Jan 26, 2006	Jan	NEWA
	25MG	N21938 002	Jan 26, 2006	Jan	NEWA
+	50MG	N21938 003	Jan 26, 2006	Jan	NEWA

TECHNETIUM TC-99M APCITIDE

INJECTABLE; INJECTION
ACUTECT

>D>	BERLEX LABS	N/A	N20887 001 Sep 14, 1998 Apr CAHN
>A>	CIS BIO INTL SA	N/A	N20887 001 Sep 14, 1998 Apr CAHN

TECHNETIUM TC-99M DEPREOTIDE

INJECTABLE; INJECTION
NEO TECT KIT

>D>	+ BERLEX LABS	N/A	N21012 001 Aug 03, 1999 Apr CAHN
>A>	+ CIS BIO INTL SA	N/A	N21012 001 Aug 03, 1999 Apr CAHN

TERCONAZOLE

SUPPOSITORY; VAGINAL
TERAZOL 3

AB	+ ORTHO MCNEIL PHARM	80MG	N19641 001 May 24, 1988 Mar CFTG
	TERCONAZOLE		
AB	PERRIGO NEW YORK	80MG	N77149 001 Mar 17, 2006 Mar NEWA

TESTOSTERONE

GEL; TRANSDERMAL
ANDROGEL

AB	+ UNIMED PHARMS	1%	N21015 001 Feb 28, 2000 Jan CTEC
	TESTOSTERONE		
AB	WATSON LABS	1%	N76737 001 Jan 27, 2006 Jan NEWA

TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION
DELATESTRYL

AO	+ INDEVUS PHARMS	200MG/ML	N09165 003 Jan CAHN
	@	200MG/ML	N09165 001 Jan CAHN

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL
ACHROMYCIN V

>D>	@ CLONMEL HLTHCARE	250MG	N50278 003 Apr CAHN
>D>	@	500MG	N50278 001 Apr CAHN
>A>	@ SCIREG INTL INC	250MG	N50278 003 Apr CAHN
>A>	@	500MG	N50278 001 Apr CAHN

THALLOUS CHLORIDE, TL-201

INJECTABLE; INJECTION
THALLOUS CHLORIDE TL 201

AP	TRACE RADIOCHEMICALS	1mCi/ML	N75569 001 Nov 21, 2001 Feb CAHN
----	----------------------	---------	----------------------------------

THEOPHYLLINE

TABLET, EXTENDED RELEASE; ORAL
THEOPHYLLINE

>A>	AB NOSTRUM	400MG	N40595 001 Apr 21, 2006 Apr NEWA
>A>	AB	600MG	N40560 002 Apr 21, 2006 Apr NEWA
	UNIPHYL		
>D>	+ PURDUE FREDERICK	400MG	N87571 001 Sep 01, 1982 Apr CTEC
>A>	AB +	400MG	N87571 001 Sep 01, 1982 Apr CTEC
>D>	+	600MG	N40086 001 Apr 15, 1996 Apr CTEC

TABLET, EXTENDED RELEASE; ORAL
UNIPHYL

>A> AB + PURDUE FREDERICK 600MG N40086 001 Apr 15, 1996 Apr CTEC

TINIDAZOLE

TABLET; ORAL
TINDAMAX
MISSION PHARMA 250MG N21618 001 May 17, 2004 Jan CAHN
+ 500MG N21618 002 May 17, 2004 Jan CAHN

TRAMADOL HYDROCHLORIDE

TABLET; ORAL
TRAMADOL HYDROCHLORIDE
@ IVAX PHARMS 50MG N75963 001 Jul 03, 2002 Jan DISC

TRIAMCINOLONE DIACETATE

INJECTABLE; INJECTION
ARISTOCORT
@ SANDOZ 25MG/ML N11685 003 Jan CAHN
@ 40MG/ML N12802 001 Jan CAHN

TRIAMCINOLONE HEXACETONIDE

INJECTABLE; INJECTION
ARISTOSPAN
+ SANDOZ 5MG/ML N16466 001 Jan CAHN
+ 20MG/ML N16466 002 Jan CAHN

TRIPELENNAMINE HYDROCHLORIDE

TABLET; ORAL
PBZ
@ NOVARTIS 50MG N05914 002 Jan DISC

TROLEANDOMYCIN

CAPSULE; ORAL
TAO
@ PFIZER EQ 250MG BASE N50336 002 Mar DISC

UNOPROSTONE ISOPROPYL

SOLUTION/DROPS; OPHTHALMIC
RESCULA
+ R TECH UENO LTD 0.15% N21214 001 Aug 03, 2000 Feb CAHN

UROKINASE

INJECTABLE; INJECTION
ABOKINASE
>D> @ ABBOTT 5,000 IU/VIAL N21846 003 Apr CAHN
>D> @ 9,000 IU/VIAL N21846 002 Apr CAHN
>D> + 250,000 IU/VIAL N21846 001 Apr CAHN
>A> @ IMARX THERAP 5,000 IU/VIAL N21846 003 Apr CAHN
>A> @ 9,000 IU/VIAL N21846 002 Apr CAHN
>A> + 250,000 IU/VIAL N21846 001 Apr CAHN

VECURONIUM BROMIDE

INJECTABLE; INJECTION

VECURONIUM BROMIDE

AP + BEDFORD 20MG/VIAL N75549 002 Jun 13, 2000 Jan CRLD

ZIDOVUDINE

CAPSULE; ORAL

RETROVIR

AB + GLAXOSMITHKLINE 100MG N19655 001 Mar 19, 1987 Mar CFTG

ZIDOVUDINE

AB AUROBINDO PHARMA LTD 100MG N78128 001 Mar 27, 2006 Mar NEWA

ZIPRASIDONE HYDROCHLORIDE

SUSPENSION; ORAL

GEODON

+ PFIZER INC EQ 10MG BASE/ML

N21483 001 Mar 29, 2006 Mar NEWA

ZONISAMIDE

CAPSULE; ORAL

ZONISAMIDE

AB GLENMARK PHARMS 25MG N77651 001 Jan 30, 2006 Jan NEWA

AB 50MG N77651 002 Jan 30, 2006 Jan NEWA

AB 100MG N77651 003 Jan 30, 2006 Jan NEWA

AB SUN PHARM IND (IN) 25MG N77634 001 Mar 17, 2006 Mar NEWA

AB 50MG N77634 002 Mar 17, 2006 Mar NEWA

AB 100MG N77634 003 Mar 17, 2006 Mar NEWA

>A> AB WATSON LABS 25MG N77650 001 Apr 20, 2006 Apr NEWA

>A> AB 50MG N77650 002 Apr 20, 2006 Apr NEWA

>A> AB 100MG N77650 003 Apr 20, 2006 Apr NEWA

OTC DRUG PRODUCT LIST - 26TH EDITION

OTC DRUG PRODUCT LIST - CUMULATIVE SUPPLMENT 4 - April 2006

2-1

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SPONGE; TOPICAL

CHLORAPREP WITH TINT

>A> + MEDI FLEX INC 2%;70% (10.5ML) N20832 005 Apr 03, 2006 Apr NEWA

CROMOLYN SODIUM

SPRAY, METERED; NASAL

CROMOLYN SODIUM

ALPHARMA US PHARMS 5.2MG/SPRAY

N74800 001 Jul 26, 2001 Jan CPOT

+ BAUSCH AND LOMB 5.2MG/SPRAY

N75702 001 Jul 03, 2001 Jan CRLD

NASALCROM

@ PHARMACIA UPJOHN 5.2MG/SPRAY

N20463 001 Jan 03, 1997 Jan DISC

KETOPROFEN

TABLET; ORAL

ACTRON

@ BAYER 12.5MG

N20499 001 Oct 06, 1995 Feb DISC

ORUDIS KT

@ WYETH CONS 12.5MG

N20429 001 Oct 06, 1995 Feb DISC

LOPERAMIDE HYDROCHLORIDE

SUSPENSION; ORAL

IMODIUM A-D

+ MCNEIL 1MG/7.5ML

N19487 002 Jul 08, 2004 Mar CDFR

LORATADINE

TABLET; ORAL

LORATADINE

APOTEX 10MG

N76471 001 Feb 14, 2006 Jan NEWA

MINOXIDIL

AEROSOL, FOAM; TOPICAL

MEN'S ROGAINE

+ PHARMACIA AND UPJOHN 5%

N21812 001 Jan 20, 2006 Jan NEWA

NAPROXEN SODIUM

CAPSULE; ORAL

NAPROXEN SODIUM

+ BANNER PHARMACAPS EQ 200MG BASE

N21920 001 Feb 17, 2006 Feb NEWA

NICOTINE POLACRILEX

GUM, CHEWING; BUCCAL

NICORETTE

>D> GLAXOSMITHKLINE EQ 2MG BASE

N18612 003 Dec 23, 1998 Apr CTNA

EQ 2MG BASE

N18612 004 Sep 25, 2000 Mar CRLD

EQ 2MG BASE

N18612 003 Dec 23, 1998 Mar CRLD

>D> GLAXOSMITHKLINE EQ 4MG BASE

N20066 003 Dec 23, 1998 Apr CTNA

EQ 4MG BASE

N20066 003 Dec 23, 1998 Mar CRLD

EQ 4MG BASE

N20066 004 Sep 25, 2000 Mar CRLD

>A> NICORETTE (MINT)

N18612 003 Dec 23, 1998 Apr CTNA

GLAXOSMITHKLINE EQ 2MG BASE

N20066 003 Dec 23, 1998 Apr CTNA

EQ 4MG BASE

N20066 003 Dec 23, 1998 Apr CTNA

GUM, CHEWING; BUCCAL

>A>	NICOTINE POLACRILEX							
>A>	PERRIGO	EQ 2MG BASE	N76776	001	Sep 16,	2004	Apr	CTNA
>A>		EQ 2MG BASE	N76777	001	Sep 16,	2004	Apr	CTNA
>A>		EQ 4MG BASE	N76778	001	Sep 16,	2004	Apr	CTNA
>A>		EQ 4MG BASE	N76779	001	Sep 16,	2004	Apr	CTNA
>A>	WATSON LABS	EQ 2MG BASE	N76569	001	Jul 29,	2004	Apr	CTNA
>A>		EQ 4MG BASE	N76568	002	Jul 29,	2004	Apr	CTNA
>D>	NICOTINE POLACRILEX (MINT)							
>D>	PERRIGO	EQ 2MG BASE	N76777	001	Sep 16,	2004	Apr	CTNA
>D>		EQ 4MG BASE	N76779	001	Sep 16,	2004	Apr	CTNA
>D>	WATSON LABS	EQ 2MG BASE	N76569	001	Jul 29,	2004	Apr	CTNA
>D>		EQ 4MG BASE	N76568	002	Jul 29,	2004	Apr	CTNA
>D>	NICOTINE POLACRILEX (ORANGE)							
>D>	PERRIGO	EQ 2MG BASE	N76776	001	Sep 16,	2004	Apr	CTNA
>D>		EQ 4MG BASE	N76778	001	Sep 16,	2004	Apr	CTNA
TROCHE/LOZENGE; ORAL								
	NICOTINE POLACRILEX							
	PERRIGO R AND D	EQ 2MG BASE	N77007	001	Jan 31,	2006	Jan	NEWA
		EQ 4MG BASE	N77007	002	Jan 31,	2006	Jan	NEWA

RANITIDINE HYDROCHLORIDE

TABLET; ORAL								
RANITIDINE								
WOCKHARDT	EQ 75MG BASE	N76760	001	Feb 24,	2006	Feb	NEWA	

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 04 APRIL 2006

NO APRIL 2006 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO APRIL 2006 ADDITIONS

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES		EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ABACAVIR SULFATE; LAMIVUDINE - EPZICOM</u>							
021652 001	5034394	Dec	18, 2011	DS	DP	D-40	Aug 02, 2007
	5034394*PED	Jun	18, 2012				
	5047407	Nov	17, 2009	DS	DP	U-257	
	5047407*PED	May	17, 2010				
	5089500	Jun	26, 2009			U-257	
	5089500*PED	Dec	26, 2009				
	5905082	May	18, 2016	DS	DP		
	5905082*PED	Nov	18, 2016				
	6294540	May	14, 2018	DS	DP	U-257	
	6294540*PED	Nov	14, 2018				
<u>ALBUTEROL SULFATE - PROAIR HFA</u>							
021457 001						I-235	Feb 03, 2009
<u>ALBUTEROL SULFATE - VENTOLIN HFA</u>							
020983 001	>A> 6131566	Apr	14, 2015	DP	U-716		
	>A> 6131566	Apr	14, 2015	DP	U-589		
	>A> 6532955	Apr	14, 2015	DP	U-716		
	>A> 6532955	Apr	14, 2015	DP	U-590		
<u>ALENDRONATE SODIUM; CHOLECALCIFEROL - FOSAMAX PLUS D</u>							
021762 001						NC	Apr 07, 2008
<u>ALFUZOSIN HYDROCHLORIDE - UROXATRAL</u>							
021287 001	4661491	May	27, 2007			U-706	
<u>AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - LOTREL</u>							
020364 006						>A> NS	Apr 11, 2009
<u>AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - LOTREL</u>							
020364 007						>A> NS	Apr 11, 2009
<u>ANIDULAFUNGIN - ERAKIS</u>							
021632 001	5965525	Oct	12, 2016	DS	DP	U-540	
	6384013	Mar	19, 2012	DS			
	6743777	Mar	19, 2012	DP		U-540	
	6960564	Apr	12, 2021	DP		U-540	
<u>APREPITANT - EMEND</u>							
021549 001	5145684	Jan	25, 2011			DP	
<u>APREPITANT - EMEND</u>							
021549 002	5145684	Jan	25, 2011			DP	
<u>ARIPIPRAZOLE - ABILIFY</u>							
021436 001						I-488	Mar 01, 2008
<u>ARIPIPRAZOLE - ABILIFY</u>							
021436 002						I-488	Mar 01, 2008
<u>ARIPIPRAZOLE - ABILIFY</u>							
021436 003						I-488	Mar 01, 2008
<u>ARIPIPRAZOLE - ABILIFY</u>							
021436 004						I-488	Mar 01, 2008
<u>ARIPIPRAZOLE - ABILIFY</u>							
021436 005						I-488	Mar 01, 2008
<u>ARIPIPRAZOLE - ABILIFY</u>							
021436 006						I-488	Mar 01, 2008
<u>ARIPIPRAZOLE - ABILIFY</u>							
021713 001	6977257	Apr	24, 2022	DS	DP	I-488	Mar 01, 2008
<u>ARTICAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE - SEPTOCAIN</u>							
022010 001						>A> NP	Mar 30, 2009
<u>AZELASTINE HYDROCHLORIDE - ASTELIN</u>							
020114 001						D-102	Feb 17, 2009
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE - TACLONEX</u>							
021852 001	4866048	Dec	29, 2007	DS	DP	U-88	
	4866048	Dec	29, 2007	DS	DP	U-193	
	5763426	Jun	09, 2015	DS	DP		
	6753013	Jan	27, 2020	DP		U-88	
	6753013	Jan	27, 2020	DP		U-193	

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BIVALIRUDIN - ANGIOMAX</u>				I-486	Nov 30, 2008
020873 001					
<u>BORTEZOMIB - VELCADE</u>				ODE	Mar 25, 2012
021602 001					
<u>BRIMONIDINE TARTRATE - ALPHAGAN P</u>					
021770 001	5424078	Jun 13, 2012	DP		
	5424078*PED	Dec 13, 2012			
	6562873	Jul 10, 2021	DP		
	6562873*PED	Jan 10, 2022			
	6627210	Jul 18, 2021	DP		
	6627210*PED	Jan 18, 2022			
	6641834	Jul 28, 2021	DP		
	6641834*PED	Jan 28, 2022			
	6673337	Jul 26, 2021	DP		
	6673337*PED	Jan 26, 2022			
<u>BROMFENAC SODIUM - XIBROM</u>					
021664 001				I-485	Jan 27, 2009
<u>BUDESONIDE - PULMICORT RESPULES</u>					
020929 001	6899099	Dec 23, 2018	U-645		
	6899099*PED	Jun 23, 2019			
<u>BUDESONIDE - PULMICORT RESPULES</u>					
020929 002	6899099	Dec 23, 2018	U-645		
	6899099*PED	Jun 23, 2019			
<u>BUDESONIDE - RHINOCORT</u>					
020746 001	6986904	Apr 29, 2017	DP U-699		
<u>BUDESONIDE - RHINOCORT</u>					
020746 002	6986904	Apr 29, 2017	DP U-699		
<u>CALCIUM CARBONATE; RISEDRONATE SODIUM - ACTONEL WITH CALCIUM (COPACKAGED)</u>					
021823 001				M-52	Jan 24, 2009
<u>CEFDITOREN PIVOXIL - SPECTRACEF</u>					
021222 001	>A> 4839350	Apr 14, 2009	DS DP		
<u>CETIRIZINE HYDROCHLORIDE - ZYRTEC</u>					
019835 001	>A> 4525358	Jun 25, 2007	DS DP	U-565	
	>A> 4525358*PED	Dec 25, 2007			
<u>CETIRIZINE HYDROCHLORIDE - ZYRTEC</u>					
019835 002	>A> 4525358	Jun 25, 2007	DS DP	U-565	
	>A> 4525358*PED	Dec 25, 2007			
<u>CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - ZYRTEC-D 12 HOUR</u>					
021150 001	>A> 7014867	Jun 10, 2022	DP		
<u>CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP SINGLE SWABSTICK</u>					
021555 002	5690958	Sep 30, 2016	DP		
<u>CICLOPIROX - LOPROX</u>					
020519 001	7018656	Sep 05, 2018	DP		
	7026337	Apr 02, 2018		U-714	
<u>CONIVAPTAN HYDROCHLORIDE - VAPRISOL</u>					
021697 001	5723606	Mar 03, 2015	DS DP	U-698	
<u>DESFLURANE - SUPRANE</u>					
020118 001	5617906	Apr 08, 2014	DP		
<u>DESLORATADINE - CLARINEX</u>					
021165 001	>A> 4659716	Mar 31, 2007	DP	U-725	
	>A> 4659716	Mar 31, 2007	DP	U-427	
	>A> 4659716*PED	Oct 01, 2007		U-427	
<u>DESLORATADINE - CLARINEX</u>					
021300 001	>A> 4659716	Mar 31, 2007	DP	U-725	
	>A> 4659716	Mar 31, 2007	DP	U-611	
	>A> 4659716*PED	Oct 01, 2007			
<u>DESLORATADINE - CLARINEX</u>					
021312 001	>A> 4659716	Mar 31, 2007	DP	U-725	
	>A> 4659716	Mar 31, 2007	DP	U-427	
	>A> 4659716*PED	Oct 01, 2007		U-427	

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES		EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DESLORATADINE - CLARINEX</u>							
021312 002	>A> 4659716	Mar	31, 2007	DP	U-725		
	>A> 4659716	Mar	31, 2007	DP	U-427		
	>A> 4659716*PED	Oct	01, 2007	DP			
<u>DESLORATADINE; PSEUDOEPHEDRINE SULFATE - CLARINEX D 24 HOUR</u>							
021605 001	>A> 4659716	Mar	31, 2007	DP	U-726		
	>A> 4659716	Mar	31, 2007	DP	U-644		
	>A> 4659716*PED	Oct	01, 2007				
	6979463	Mar	28, 2022	DP			
<u>DESLORATADINE; PSEUDOEPHEDRINE SULFATE - CLARINEX-D 12 HOUR</u>							
021313 001	>A> 4659716	Mar	31, 2007	DP	U-707	NCE	Dec 21, 2006
	>A> 4659716*PED	Oct	01, 2007			NC	Mar 03, 2008
	6100274	Jul	07, 2019	DP		PED	Jun 21, 2007
	6100274*PED	Jan	07, 2010				
	6709676	Feb	18, 2021	DP	U-707		
<u>DOCETAXEL - TAXOTERE</u>							
020449 001	5750561	Jul	03, 2012	DP		I-490	Mar 22, 2009
<u>DONEPEZIL HYDROCHLORIDE - ARICEPT ODT</u>							
021720 001	4895841	Nov	25, 2010	DS	DP	U-713	
<u>DONEPEZIL HYDROCHLORIDE - ARICEPT ODT</u>							
021720 002	4895841	Nov	25, 2010	DS	DP	U-713	
<u>DROSPIRENONE; ETHINYL ESTRADIOL - YAZ</u>							
021676 001	>A> 5569652	Oct	29, 2013		U-1	NP	
	>A> 5798338	Jul	10, 2015	DP			
	>A> 6787531	Aug	31, 2020	DP			
	>A> 6933395	Aug	11, 2017	DP			
	>A> RE37564	Jun	30, 2014	DP			
	>A> RE37838	Jun	30, 2014	DP			
	>A> RE38253	Jun	30, 2014	DP			
<u>EPLERENONE - INSPRA</u>							
021437 001	>A> 4559332	Apr	09, 2007	DS	DP	U-537	
<u>EPLERENONE - INSPRA</u>							
021437 002	>A> 4559332	Apr	09, 2007	DS	DP	U-537	
<u>EPLERENONE - INSPRA</u>							
021437 003	>A> 4559332	Apr	09, 2007	DS	DP	U-537	
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>							
021153 001	>A> 4738974	Apr	19, 2007	DS	DP	U-635	I-484
	>A> 4738974	Apr	19, 2007	DS	DP	U-373	>A> NPP
	>A> 4738974*PED	Oct	19, 2007			U-373	
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>							
021153 002	>A> 4738974	Apr	19, 2007	DS	DP	U-635	I-484
	>A> 4738974	Apr	19, 2007	DS	DP	U-373	>A> NPP
	>A> 4738974*PED	Oct	19, 2007			U-373	
<u>ETHINYL ESTRADIOL; NORELGESTROMIN - ORTHO EVRA</u>							
021180 001	5876746	Nov	20, 2015	DP	U-514		
<u>ETHINYL ESTRADIOL; NORETHINDRONE - OVCON-35</u>							
021490 001	>A> 6667050	Apr	06, 2019	DP	U-1		
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - LOESTRIN 24 FE</u>							
021871 001	5552394	Jul	22, 2014		U-1	NP	
<u>FENOFIBRATE - FENOFIBRATE</u>							
076433 001						PC	May 22, 2006
<u>FENOFIBRATE - FENOFIBRATE</u>							
076433 002						PC	May 22, 2006
<u>FENOFIBRATE - LIPOFEN</u>							
021612 001	5545628	Jan	10, 2015		U-701		
<u>FENOFIBRATE - LIPOFEN</u>							
021612 002	5545628	Jan	10, 2015		U-701		
<u>FENOFIBRATE - LIPOFEN</u>							
021612 003	5545628	Jan	10, 2015		U-701		

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FENOFIBRATE - TRICOR					
021656 001	>A> 7037529	Jan 09, 2018	DP		
	>A> 7041319	Jan 09, 2018	DP		
FENOFIBRATE - TRICOR					
021656 002	>A> 7037529	Jan 09, 2018	DP		
	>A> 7041319	Jan 09, 2018	DP		
FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - ALLEGRA D 24 HOUR					
021704 001	>A> RE39069	May 29, 2018	DP		
FLUNISOLIDE - AEROSPIN HFA					
021247 001				NP	Jan 27, 2009
FLUOCINOLONE ACETONIDE - RETISERT					
021737 001	6217895	Mar 22, 2019	DP	U-708	
	6548078	Mar 22, 2019	DP	U-708	
FLUOCINONIDE - VANOS					
021758 001				I-487	Mar 02, 2009
FLUOXETINE HYDROCHLORIDE - PROZAC WEEKLY					
021235 001	RE39030	May 29, 2017	DP	U-397	
	RE39030	May 29, 2017	DP	U-396	
FLUTICASONE PROPIONATE - FLOVENT HFA					
021433 001	5658549	Sep 19, 2014	DP	U-710	NPP
	5674472	Oct 07, 2014	DP		Feb 28, 2009
	6251368	Dec 04, 2012	DP		
FLUTICASONE PROPIONATE - FLOVENT HFA					
021433 002	5658549	Sep 19, 2014	DP	U-710	NPP
	5674472	Oct 07, 2014	DP		Feb 28, 2009
	6251368	Dec 04, 2012	DP		
FLUTICASONE PROPIONATE - FLOVENT HFA					
021433 003	5658549	Sep 19, 2014	DP	U-710	NPP
	5674472	Oct 07, 2014	DP		Feb 28, 2009
	6251368	Dec 04, 2012	DP		
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 100/50					
021077 001	4992474	Feb 12, 2008		U-211	
	4992474*PED	Aug 12, 2008		U-211	
	5126375	Feb 12, 2008			
	5126375*PED	Aug 12, 2008			
	5225445	Feb 12, 2008		U-211	
	5225445*PED	Aug 12, 2008		U-211	
	6536427	Mar 01, 2011	DP		
	6536427*PED	Sep 01, 2011			
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 250/50					
021077 002	4992474	Feb 12, 2008		U-211	
	4992474*PED	Aug 12, 2008		U-211	
	5126375	Feb 12, 2008			
	5126375*PED	Aug 12, 2008			
	5225445	Feb 12, 2008		U-211	
	5225445*PED	Aug 12, 2008		U-211	
	6536427	Mar 01, 2011	DP		
	6536427*PED	Sep 01, 2011			
FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 500/50					
021077 003	4992474	Feb 12, 2008		U-211	
	4992474*PED	Aug 12, 2008		U-211	
	5126375	Feb 12, 2008			
	5126375*PED	Aug 12, 2008			
	5225445	Feb 12, 2008		U-211	
	5225445*PED	Aug 12, 2008		U-211	
	6536427	Mar 01, 2011	DP		
	6536427*PED	Sep 01, 2011			
FROVATRIPTAN SUCCINATE - FROVA					
021006 001	5464864	Nov 07, 2015		U-436	
FULVESTRANT - FASLODEX					
021344 001	4659516	Oct 01, 2006			

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>GLIMEPIRIDE - AMARYL</u>						
	020496 001				M-54 PED	Nov 28, 2008 May 28, 2009
<u>GLIMEPIRIDE - AMARYL</u>						
	020496 002				M-54 PED	Nov 28, 2008 May 28, 2009
<u>GLIMEPIRIDE - AMARYL</u>						
	020496 003				M-54 PED	Nov 28, 2008 May 28, 2009
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
021700 001	5002953	Sep 17, 2011	DS	DP	U-690	
	5002953*PED	Mar 17, 2012				
	5741803	Apr 21, 2015	DS	DP	U-690	
	5741803*PED	Oct 21, 2015				
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
021700 002	5002953	Sep 17, 2011	DS	DP	U-690	
	5002953*PED	Mar 17, 2012				
	5741803	Apr 21, 2015	DS	DP	U-690	
	5741803*PED	Oct 21, 2015				
<u>GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL</u>						
021700 003	5002953	Sep 17, 2011	DS	DP	U-690	
	5002953*PED	Mar 17, 2012				
	5741803	Apr 21, 2015	DS	DP	U-690	
	5741803*PED	Oct 21, 2015				
<u>HYALURONIDASE RECOMBINANT HUMAN - HYLENEX RECOMBINANT</u>						
021859 001					NCE	Dec 02, 2010
<u>HYDROCHLOROTHIAZIDE; VALSARTAN - DIOVAN HCT</u>						
020818 004					>A> NS	Apr 28, 2009
<u>HYDROCHLOROTHIAZIDE; VALSARTAN - DIOVAN HCT</u>						
020818 005					>A> NS	Apr 28, 2009
<u>IBANDRONATE SODIUM - BONIVA</u>						
021455 001	4927814	Jul 09, 2007	DS	DP	U-642	
	6143326	Apr 21, 2017			U-642	
<u>IBANDRONATE SODIUM - BONIVA</u>						
021858 001	4927814	Jul 09, 2007	DS	DP	U-700	
					NDF	Jan 06, 2009
					NCE	May 16, 2008
<u>IBUPROFEN LYSINE - NEOPROFEN</u>						
021903 001					>A> NE	Apr 13, 2009
					>A> ODE	Apr 13, 2013
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR</u>						
021536 001					I-489	Oct 19, 2008
<u>INSULIN RECOMBINANT HUMAN - EXUBERA</u>						
021868 001	5740794	Apr 21, 2015	DP		NP	Jan 27, 2009
	5997848	Mar 07, 2014		U-704		
	6051256	Mar 07, 2014	DP			
	6257233	May 14, 2019		U-704		
	6423344	Mar 07, 2014	DP			
	6543448	Sep 21, 2014	DP			
	6546929	May 14, 2019		U-704		
	6582728	Jun 24, 2020	DP			
	6592904	Mar 07, 2014	DP			
	6685967	Sep 11, 2018	DP			
	6737045	Mar 07, 2014		U-704		
	RE37872	Feb 12, 2010	DP			
	RE38385	Feb 12, 2010	DP			

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN RECOMBINANT HUMAN - EXUBERA</u>						
021868 002	5740794	Apr	21, 2015	DP	NP	Jan 27, 2009
	5997848	Mar	07, 2014	DP	U-704	
	6051256	Mar	07, 2014	DP	U-704	
	6257233	May	14, 2019	DP	U-704	
	6423344	Mar	07, 2014	DP	U-704	
	6543448	Sep	21, 2014	DP	U-704	
	6546929	May	14, 2019	DP	U-704	
	6582728	Jun	24, 2020	DP	U-704	
	6592904	Mar	07, 2014	DP	U-704	
	6685967	Sep	11, 2018	DP	U-704	
	6737045	Mar	07, 2014	DP	U-704	
	RE37872	Feb	12, 2010	DP	U-704	
	RE38385	Feb	12, 2010	DP	U-704	
<u>IPRATROPIUM BROMIDE - ATROVENT HFA</u>						
021527 001	6983743	May	26, 2020	DP		
<u>LANSOPRAZOLE - PREVACID</u>						
020406 001	6749864	Feb	13, 2007	DP		
<u>LANSOPRAZOLE - PREVACID</u>						
020406 002	6749864	Feb	13, 2007	DP		
<u>LANSOPRAZOLE - PREVACID</u>						
021281 001	6749864	Feb	13, 2007	DP		
<u>LANSOPRAZOLE - PREVACID</u>						
021281 002	6749864	Feb	13, 2007	DP		
<u>LANSOPRAZOLE - PREVACID</u>						
021428 001	6749864	Feb	13, 2007	DP		
<u>LANSOPRAZOLE - PREVACID</u>						
021428 002	6749864	Feb	13, 2007	DP		
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
021468 003	5968976	Mar	19, 2016	DP	U-613	
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
021468 004	5968976	Mar	19, 2016	DP	U-613	
<u>LENALIDOMIDE - REVLIMID</u>						
021880 001	5635517	Jul	24, 2016	DS	ODE	Dec 27, 2012
	6045501	Aug	28, 2018	DP	U-694	
	6315720	Oct	23, 2020	DP	U-694	
	6555554	Jul	24, 2016	DP	U-694	
	6561976	Aug	28, 2018	DP	U-694	
	6561977	Oct	23, 2020	DP	U-694	
	6755784	Oct	23, 2020	DP	U-694	
	6908432	Aug	28, 2018	DP	U-694	
<u>LENALIDOMIDE - REVLIMID</u>						
021880 002	5635517	Jul	24, 2016	DS	ODE	Dec 27, 2012
	6045501	Aug	28, 2018	DP	U-694	
	6315720	Oct	23, 2020	DP	U-694	
	6555554	Jul	24, 2016	DP	U-694	
	6561976	Aug	28, 2018	DP	U-694	
	6561977	Oct	23, 2020	DP	U-694	
	6755784	Oct	23, 2020	DP	U-694	
	6908432	Aug	28, 2018	DP	U-694	
<u>LEVETIRACETAM - KEPPTA</u>						
021035 004				>A> NPP		Jun 21, 2008
<u>LIDOCAINE; TETRACAINE - SYNERA</u>						
021623 001				NC		Jun 23, 2009

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES		EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LOPINAVIR; RITONAVIR - KALETRA</u>							
021906 001	5541206	Jul	30, 2013	DS	DP	U-688	
	5541206*PED	Jan	30, 2014			U-688	
	5635523	Jun	03, 2014				
	5635523*PED	Dec	03, 2014				
	5648497	Jul	15, 2014	DS	DP		
	5648497*PED	Jan	15, 2015				
	5674882	Oct	07, 2014			U-688	
	5674882*PED	Apr	07, 2015				
	5846987	Dec	29, 2012			U-688	
	5846987*PED	Jun	29, 2013				
	5886036	Dec	29, 2012	DP			
	5886036*PED	Jun	29, 2013				
	6037157	Jun	26, 2016			U-688	
	6037157*PED	Dec	26, 2016				
	6703403	Jun	26, 2016			U-688	
	6703403*PED	Dec	26, 2016				
<u>LOVASTATIN; NIACIN - ADVICOR</u>							
021249 001	7011848	Sep	20, 2013			U-712	
<u>LOVASTATIN; NIACIN - ADVICOR</u>							
021249 002	7011848	Sep	20, 2013			U-712	
<u>LOVASTATIN; NIACIN - ADVICOR</u>							
021249 003	7011848	Sep	20, 2013			U-712	
<u>LUBIPROSTONE - AMITIZA</u>							
021908 001	>A> 5284858	Feb	08, 2011	DS	DP		
	>A> 5317032	May	31, 2011	DS	DP	U-717	
	>A> 6414016	Sep	05, 2020	DS	DP	U-717	
	>A> 6583174	Oct	16, 2020	DS	DP		
<u>MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>							
021850 001	>A> 6645988	Jul	16, 2016	DS	DP	U-623	
	>A> 6645988	Jul	16, 2016	DS	DP	U-588	
<u>MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>							
021850 002	>A> 6645988	Jul	16, 2016	DS	DP	U-623	
	>A> 6645988	Jul	16, 2016	DS	DP	U-588	
<u>MECASERMIN RINFABATE RECOMBINANT - IPLEX</u>							
021884 001	5200509	Apr	06, 2010	DS			
	5681818	Oct	28, 2014			U-697	
<u>MELOXICAM - MOBIC</u>							
020938 001						ODE	Aug 11, 2012
						PED	Feb 11, 2013
<u>MELOXICAM - MOBIC</u>							
020938 002						ODE	Aug 11, 2012
						PED	Feb 11, 2013
<u>MELOXICAM - MOBIC</u>							
021530 001						I-469	Aug 11, 2008
						ODE	Aug 11, 2012
						PED	Feb 11, 2013
						PED	Feb 11, 2009
<u>MEQUINOL; TRETINOIN - SOLAGE</u>							
020922 001	>A> 5194247	Dec	10, 2013	DP	U-294		
<u>MICONAZOLE NITRATE; PETROLATUM, WHITE; ZINC OXIDE - VUSION</u>							
021026 001	>A> 4911932	Mar	27, 2007	DP	U-718	NP	Feb 16, 2009
<u>MINOXIDIL - MEN'S ROGAINE</u>							
021812 001	6946120	Apr	20, 2019	DP	U-702	NDF	Jan 20, 2009
<u>MODAFINIL - PROVIGIL</u>							
020717 001	4927855	May	22, 2007		U-255	I-449	Jan 23, 2007
	4927855*PED	Nov	22, 2007			ODE	Dec 24, 2005
	RE37516	Oct	06, 2014		U-255	PED	Jul 23, 2007
	RE37516*PED	Apr	06, 2015			PED	Jun 24, 2006

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MODAFINIL - PROVIGIL</u>						
020717 002	4927855	May	22, 2007	U-255	I-449	Jan 23, 2007
	4927855*PED	Nov	22, 2007		ODE	Dec 24, 2005
	RE37516	Oct	06, 2014	U-255	PED	Jul 23, 2007
	RE37516*PED	Apr	06, 2015		PED	Jun 24, 2006
<u>MORPHINE SULFATE - KADIAN</u>						
020616 004	5378474	Mar	23, 2010			
<u>MORPHINE SULFATE - KADIAN</u>						
020616 005	5202128	Apr	13, 2010			
	5378474	Mar	23, 2010			
<u>MOXIFLOXACIN HYDROCHLORIDE - AVELOX</u>						
021085 001	4990517	Dec	08, 2011	DS DP	U-298	
	6610327	Oct	29, 2019	DP	U-298	
<u>MOXIFLOXACIN HYDROCHLORIDE - AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER</u>						
021277 001	4990517	Dec	08, 2011	DS DP	U-298	
	6548079	Jul	25, 2020	DP	U-298	
<u>MOXIFLOXACIN HYDROCHLORIDE - VIGAMOX</u>						
021598 001	4990517	Dec	08, 2011	DS DP	U-709	
	4990517*PED	Jun	08, 2012			
<u>NALTREXONE - VIVITROL</u>						
021897 001					>A> NDF	Apr 13, 2009
<u>NELARABINE - ARRANON</u>						
021877 001	5747472	Feb	20, 2013	U-696		
	5747472	Feb	20, 2013	U-695		
	5747472	Feb	20, 2013	U-689		
	5821236	Feb	20, 2013	U-695		
<u>NIACIN - NIASPIN</u>						
020381 001	7011848	Sep	20, 2013	U-712		
<u>NIACIN - NIASPIN</u>						
020381 002	7011848	Sep	20, 2013	U-712		
<u>NIACIN - NIASPIN</u>						
020381 003	7011848	Sep	20, 2013	U-712		
<u>NIACIN - NIASPIN</u>						
020381 004	7011848	Sep	20, 2013	U-712		
<u>NIACIN - NIASPIN TITRATION STARTER PACK</u>						
020381 005	7011848	Sep	20, 2013	U-712		
<u>NICOTINE POLACRILEX - NICOTINE POLACRILEX</u>						
077007 001				PC		Aug 21, 2006
<u>NICOTINE POLACRILEX - NICOTINE POLACRILEX</u>						
077007 002				PC		Aug 21, 2006
<u>OCTREOTIDE ACETATE - SANDOSTATIN</u>						
019667 001	5753618	May	19, 2015			
	5753618*PED	Nov	19, 2015			
<u>OCTREOTIDE ACETATE - SANDOSTATIN</u>						
019667 002	5753618	May	19, 2015			
	5753618*PED	Nov	19, 2015			
<u>OCTREOTIDE ACETATE - SANDOSTATIN</u>						
019667 003	5753618	May	19, 2015			
	5753618*PED	Nov	19, 2015			
<u>OCTREOTIDE ACETATE - SANDOSTATIN</u>						
019667 004	5753618	May	19, 2015			
	5753618*PED	Nov	19, 2015			
<u>OCTREOTIDE ACETATE - SANDOSTATIN</u>						
019667 005	5753618	May	19, 2015			
	5753618*PED	Nov	19, 2015			

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OCTREOTIDE ACETATE - SANDOSTATIN LAR</u>						
021008 001	5538739	Jul	23, 2013		ODE	Nov 25, 2005
	5538739*PED	Jan	23, 2014		PED	May 25, 2006
	5639480	Jun	17, 2014			
	5639480*PED	Dec	17, 2014			
	5688530	Nov	18, 2014	U-268		
	5688530*PED	May	18, 2015			
	5922338	Jul	13, 2016			
	5922338*PED	Jan	13, 2017			
	5922682	Jul	13, 2016			
	5922682*PED	Jan	13, 2017			
<u>OCTREOTIDE ACETATE - SANDOSTATIN LAR</u>						
021008 002	5538739	Jul	23, 2013		ODE	Nov 25, 2005
	5538739*PED	Jan	23, 2014		PED	May 25, 2006
	5639480	Jun	17, 2014			
	5639480*PED	Dec	17, 2014			
	5688530	Nov	18, 2014	U-268		
	5688530*PED	May	18, 2015			
	5922338	Jul	13, 2016			
	5922338*PED	Jan	13, 2017			
	5922682	Jul	13, 2016			
	5922682*PED	Jan	13, 2017			
<u>OCTREOTIDE ACETATE - SANDOSTATIN LAR</u>						
021008 003	5538739	Jul	23, 2013		ODE	Nov 25, 2005
	5538739*PED	Jan	23, 2014		PED	May 25, 2006
	5639480	Jun	17, 2014			
	5639480*PED	Dec	17, 2014			
	5688530	Nov	18, 2014	U-268		
	5688530*PED	May	18, 2015			
	5922338	Jul	13, 2016			
	5922338*PED	Jan	13, 2017			
	5922682	Jul	13, 2016			
	5922682*PED	Jan	13, 2017			
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>						
021849 001	6489346	Jul	16, 2016	DS	DP	U-588
	6645988	Jul	16, 2016	DS	DP	
	6699885	Jul	16, 2016			U-588
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>						
021849 002	>A> 6489346	Jul	16, 2016	DS	DP	U-623
	>A> 6489346	Jul	16, 2016	DS	DP	U-588
	6645988	Jul	16, 2016	DS	DP	
	>A> 6699885	Jul	16, 2016			U-623
	>A> 6699885	Jul	16, 2016			U-588
<u>OXALIPLATIN - ELOXATIN</u>						
021492 001	5420319	Aug	09, 2016	DS		
<u>OXALIPLATIN - ELOXATIN</u>						
021492 002	5420319	Aug	09, 2016	DS		
<u>OXALIPLATIN - ELOXATIN</u>						
021759 001	5420319	Aug	08, 2016	DS		
<u>OXALIPLATIN - ELOXATIN</u>						
021759 002	5420319	Aug	08, 2016	DS		
<u>OXCARBAZEPINE - TRILEPTAL</u>						
021014 001	>A> 7037525	Feb	12, 2018			U-724
<u>OXCARBAZEPINE - TRILEPTAL</u>						
021014 002	>A> 7037525	Feb	12, 2018			U-724
<u>OXCARBAZEPINE - TRILEPTAL</u>						
021014 003	>A> 7037525	Feb	12, 2018			U-724
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
020667 001	4843086	Jun	27, 2006			U-231
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
020667 002	4843086	Jun	27, 2006			U-231
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX</u>						
020667 003	4843086	Jun	27, 2006			U-231

PREScription AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY DATA

See report footnote for information regarding report content

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES		EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SELEGILINE - EMSAM</u>							
021336 003	RE34579	Aug	18, 2007	DS	DP	U-711	NDF
<u>SEVELAMER HYDROCHLORIDE - RENAGEL</u>							
021179 001	7014846	Aug	11, 2013		DP	U-246	
<u>SEVELAMER HYDROCHLORIDE - RENAGEL</u>							
021179 002	7014846	Aug	11, 2013		DP	U-246	
<u>SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE - OSMOPREP</u>							
021892 001	>A> 5616346	May	18, 2013		DP	U-715	NP
<u>SORAFENIB TOSYLATE - NEXAVAR</u>							
021923 001							ODE
<u>SUNITINIB MALATE - SUTENT</u>							
021938 001	6573293	Feb	15, 2021	DS	DP	U-703	NCE
<u>SUNITINIB MALATE - SUTENT</u>							
021938 002	6573293	Feb	15, 2021	DS	DP	U-703	NCE
<u>SUNITINIB MALATE - SUTENT</u>							
021938 003	6573293	Feb	15, 2021	DS	DP	U-703	NCE
<u>TACROLIMUS - PROGRAF</u>							
050708 001							ODE
<u>TACROLIMUS - PROGRAF</u>							
050708 002							ODE
<u>TACROLIMUS - PROGRAF</u>							
050708 003							ODE
<u>TACROLIMUS - PROGRAF</u>							
050709 001							ODE
<u>TERIPARATIDE RECOMBINANT HUMAN - FORTEO</u>							
021318 001	6977077	Aug	19, 2019			U-597	
<u>THYROTROPIN ALFA - THYROGEN</u>							
020898 001							M-53
<u>TIOTROPIUM BROMIDE MONOHYDRATE - SPIRIVA</u>							
021395 001	>A> RE38912	Oct	11, 2021		DP		
<u>TOPIRAMATE - TOPAMAX</u>							
020505 001	>A> 7018983	Oct	13, 2015			U-723	
<u>TOPIRAMATE - TOPAMAX</u>							
020505 002	>A> 7018983	Oct	13, 2015			U-723	
<u>TOPIRAMATE - TOPAMAX</u>							
020505 003	>A> 7018983	Oct	13, 2015			U-723	
<u>TOPIRAMATE - TOPAMAX</u>							
020505 004	>A> 7018983	Oct	13, 2015			U-723	
<u>TOPIRAMATE - TOPAMAX</u>							
020505 005	>A> 7018983	Oct	13, 2015			U-723	
<u>TOPIRAMATE - TOPAMAX</u>							
020505 006	>A> 7018983	Oct	13, 2015			U-723	
<u>TOPIRAMATE - TOPAMAX SPRINKLE</u>							
020844 001	>A> 7018983	Oct	13, 2015			U-723	
<u>TOPIRAMATE - TOPAMAX SPRINKLE</u>							
020844 002	>A> 7018983	Oct	13, 2015			U-723	
<u>TOPIRAMATE - TOPAMAX SPRINKLE</u>							
020844 003	>A> 7018983	Oct	13, 2015			U-723	
<u>TREPROSTINIL SODIUM - REMODULIN</u>							
021272 001	5153222	Oct	06, 2014			U-455	
<u>TREPROSTINIL SODIUM - REMODULIN</u>							
021272 002	5153222	Oct	06, 2014			U-455	
<u>TREPROSTINIL SODIUM - REMODULIN</u>							
021272 003	5153222	Oct	06, 2014			U-455	
<u>TREPROSTINIL SODIUM - REMODULIN</u>							
021272 004	5153222	Oct	06, 2014			U-455	

**PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA**

See report footnote for information regarding report content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ZANAMIVIR - RELENZA						
021036 001	>A> 5648379	Jul	15, 2014		U-722	I-491
	>A> 5648379	Jul	15, 2014		U-721	
	>A> 5648379	Jul	15, 2014		U-274	
	>A> 6294572	Dec	15, 2014	DS DP		
ZIPRASIDONE HYDROCHLORIDE - GEODON						
021483 001	>A> 4831031	Mar	02, 2007	DS DP	U-720	
	>A> 5312925	Sep	01, 2012	DS DP	U-720	
	>A> 6150366	May	27, 2019	DP	U-719	
	>A> 6245766	Dec	18, 2018		U-601	
ZOLEDRONIC ACID - ZOMETA						
021223 001	4939130	Sep	02, 2012	DS DP	U-53	
ZOLEDRONIC ACID - ZOMETA						
021223 002	4939130	Sep	02, 2012	DS DP	U-53	

Footnote:

1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents submitted on FDA Form 3542 and listed after August 18, 2003 will have one to three patent codes indicating specific patent claims as submitted by the sponsor:

DS = Drug Substance claim

DP = Drug Product claim

U and number = Method of Use claim (may be multiple). Specific Method of use claims are listed at
<http://www.fda.gov/cder/orange/patex.htm>

3. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

4. *PED and PED represent pediatric exclusivity. Patents with pediatric exclusivity granted after August 18, 2003 will be indicated with *PED as was done prior to August 18, 2003. Patents with *PED added after August 18, 2003 will not contain any information relative to the patent itself other than the *PED extension. Information related specifically to the patent will be conveyed on the original patent only.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 25th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at
<http://www.accessdata.fda.gov/scripts/cder/ob/docs/patternsall.cfm>

The current complete list of exclusivity terms is available at
<http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm>